Biotech Industry Financials, Performance and Ratios
-
Industry Score
43.8 /100
Rank 68 out of 131 Industries -
Advance/Decline
124/172
-
No. of Companies296
-
Avg. Market Cap2,116
-
Price to Earning Ratio2.29
-
Price to Earning Growth Ratio0.27
-
Price to Book Ratio17.09
-
Return on Equity36.37
-
Return on Capital Employed-
-
Return on Assets4.58
-
Dividend yield 1 year %0.35 %
-
Net Profit Growth Annual YoY %-31.18 %
-
Net Profit Growth Qtr YoY %73.55 %
-
Net Profit Growth Qtr QoQ %40.03 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Biotech Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Biotech Peer comparison
Compare all stocks in Biotech industry listed on stock exchanges
Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
---|---|---|---|---|---|---|---|---|---|---|---|
Elanco Animal Health Inc |
|
7,012.6
|
14.1
|
L
 -1.9%
H
14.1
14.5
|
L
 -5.4%
H
14.1
15.2
|
L
 -1.2%
H
14.0
15.2
|
L
 45.0%
H
9.3
15.2
|
L
 9.2%
H
8.0
15.8
|
L
 -30.3%
H
7.9
20.5
|
L
 -33.2%
H
7.9
37.5
|
L
H
7.9
37.6
|
Nuvation Bio Inc - Ordinar... |
|
820.0
|
2.4
|
L
 -2.0%
H
2.4
2.6
|
L
 2.6%
H
2.4
2.8
|
L
 24.9%
H
1.9
2.8
|
L
 10.6%
H
1.6
2.8
|
L
 -32.7%
H
1.5
4.0
|
L
 -12.7%
H
1.0
4.2
|
L
H
1.0
15.2
|
L
H
1.0
15.2
|
Arcus Biosciences Inc |
|
998.5
|
9.4
|
L
 -1.9%
H
9.3
9.9
|
L
 3.0%
H
9.2
10.3
|
L
 18.6%
H
7.9
10.3
|
L
 16.0%
H
7.1
10.7
|
L
 -40.6%
H
6.5
19.0
|
L
 -64.5%
H
6.5
36.1
|
L
 -55.4%
H
6.5
49.1
|
L
H
6.3
49.1
|
Whitehawk Therapeutics Inc. |
|
84.3
|
1.8
|
L
 1.1%
H
1.8
1.8
|
L
 -4.3%
H
1.7
2.0
|
L
 -7.3%
H
1.7
2.1
|
L
 21.8%
H
1.4
2.2
|
L
 12.6%
H
1.2
3.8
|
L
 -85.5%
H
1.2
14.8
|
L
 -91.0%
H
1.2
49.8
|
L
H
1.2
101.3
|
AbCellera Biologics Inc |
|
1,364.1
|
4.6
|
L
 -2.6%
H
4.6
4.8
|
L
 -7.1%
H
4.6
5.4
|
L
 26.6%
H
3.3
5.8
|
L
 79.2%
H
1.9
5.8
|
L
 41.5%
H
1.9
5.8
|
L
 -54.5%
H
1.9
15.0
|
L
H
1.9
71.9
|
L
H
1.9
71.9
|
Arcellx Inc |
|
3,942.3
|
71.5
|
L
 2.2%
H
70.5
74.4
|
L
 4.8%
H
68
74.4
|
L
 9.5%
H
63.1
74.4
|
L
 10.6%
H
47.9
74.4
|
L
 15.2%
H
47.9
107.4
|
L
 245.1%
H
15.6
107.4
|
L
H
6.0
107.4
|
L
H
6.0
107.4
|
Adma Biologics Inc |
|
4,438.1
|
18.6
|
L
 1.8%
H
18.4
18.9
|
L
 9.0%
H
16.8
18.9
|
L
 2.4%
H
16.5
18.9
|
L
 -22.9%
H
16.5
24.2
|
L
 50.4%
H
10.2
25.7
|
L
 768.7%
H
2.0
25.7
|
L
 554.6%
H
1.0
25.7
|
L
 104.3%
H
1.0
25.7
|
Adaptive Biotechnologies Corp |
|
1,586.0
|
10.4
|
L
 0.5%
H
10.3
10.7
|
L
 -0.9%
H
10.3
11.2
|
L
 -11.5%
H
10.2
12.4
|
L
 37.2%
H
7.2
12.4
|
L
 135.1%
H
3.8
12.4
|
L
 14.0%
H
2.3
13.2
|
L
 -72.8%
H
2.3
71.3
|
L
H
2.3
71.3
|
Aditxt Inc |
|
2.7
|
1.1
|
L
 -4.4%
H
1.1
1.2
|
L
 -11.3%
H
1.1
1.3
|
L
 -17.3%
H
1.1
1.4
|
L
 -48.8%
H
1.1
2.8
|
L
 -98.0%
H
0.0
85.6
|
L
 -100.0%
H
0.0
45584
|
L
 -100.0%
H
0.0
766400
|
L
H
0.0
766400
|
Agenus Inc |
|
161.8
|
5.9
|
L
 0.3%
H
5.8
6.2
|
L
 -3.6%
H
5.8
6.6
|
L
 24.0%
H
4.3
7.3
|
L
 93.4%
H
2.7
7.3
|
L
 -9.1%
H
1.4
7.3
|
L
 -88.3%
H
1.4
196
|
L
 -89.9%
H
1.4
196
|
L
 -96.4%
H
1.4
196
|
Aeglea BioTherapeutics Inc |
|
70.0
|
17.3
|
L
 3.1%
H
16.8
17.7
|
L
 4.9%
H
16.4
18.3
|
L
 13.6%
H
14
18.3
|
L
 13.9%
H
13.9
19.2
|
L
 13.9%
H
13.9
19.2
|
L
 66.6%
H
2.7
39
|
L
 -90.1%
H
2.7
247.5
|
L
H
2.7
318.8
|
Avalon GloboCare Corp |
|
6.4
|
2.1
|
L
 -8.4%
H
2.1
2.2
|
L
 -14.1%
H
2.1
4.7
|
L
 -25.2%
H
2.1
4.7
|
L
 -44.4%
H
2.1
4.7
|
L
 447.4%
H
0.2
11.7
|
L
 -61.8%
H
0.2
11.7
|
L
 -87.1%
H
0.2
21.6
|
L
H
0.2
135
|
Aldeyra Therapeutics Inc |
|
302.5
|
5.1
|
L
 -0.8%
H
5
5.4
|
L
 -5.8%
H
5
5.6
|
L
 33.3%
H
3.7
5.7
|
L
 87.7%
H
1.9
5.7
|
L
 28.2%
H
1.1
7.2
|
L
 0.2%
H
1.1
12.0
|
L
 -20.2%
H
1.1
16.0
|
L
 -44.7%
H
1.1
16.7
|
Alector Inc |
|
160.0
|
1.6
|
L
 -0.6%
H
1.6
1.7
|
L
 -7.0%
H
1.6
2
|
L
 8.1%
H
1.3
2
|
L
 41.6%
H
1.0
2
|
L
 -74.8%
H
0.9
6.5
|
L
 -84.3%
H
0.9
13.5
|
L
 -90.2%
H
0.9
43.3
|
L
H
0.9
43.3
|
Allogene Therapeutics Inc |
|
282.2
|
1.3
|
L
 -7.9%
H
1.3
1.5
|
L
 -9.2%
H
1.3
1.7
|
L
 9.3%
H
1.1
1.7
|
L
 -16.2%
H
0.9
1.8
|
L
 -56.7%
H
0.9
3.8
|
L
 -90.1%
H
0.9
17.5
|
L
 -96.6%
H
0.9
44.9
|
L
H
0.9
55
|
Altimmune Inc |
|
296.0
|
3.7
|
L
 -4.7%
H
3.6
3.9
|
L
 -13.1%
H
3.6
4.4
|
L
 4.3%
H
3.3
5.0
|
L
 -28.4%
H
2.9
7.7
|
L
 -44.5%
H
2.9
11.2
|
L
 -69.6%
H
2.1
23.5
|
L
 -83.8%
H
2.1
29.7
|
L
 -99.3%
H
1.5
1050
|
Alvotech |
|
2,904.8
|
9.3
|
L
 -4.5%
H
9.1
9.7
|
L
 6.9%
H
8.7
9.9
|
L
 1.5%
H
8.3
9.9
|
L
 18.1%
H
7.7
11.9
|
L
 -21.4%
H
7.4
13.7
|
L
 16.7%
H
5.5
18
|
L
H
5.2
18
|
L
H
5.2
18
|
Kalaris Therapeutics Inc. |
|
50.3
|
2.7
|
L
H
2.7
2.8
|
L
 4.7%
H
2.5
3.0
|
L
 2.7%
H
2.3
3.0
|
L
 -61.0%
H
2.3
7
|
L
 249.4%
H
0.4
12.9
|
L
 -41.4%
H
0.4
12.9
|
L
H
0.4
49.0
|
L
H
0.4
49.0
|
Amgen |
|
162,048.5
|
301.4
|
L
 -0.7%
H
299.7
305.6
|
L
 -1.4%
H
297.8
311.3
|
L
 8.8%
H
276.6
311.3
|
L
 4.4%
H
261.4
311.3
|
L
 -9.4%
H
253.3
340.9
|
L
 21.8%
H
211.7
346.9
|
L
 21.1%
H
198.6
346.9
|
L
 75.8%
H
130.1
346.9
|
AnaptysBio Inc |
|
733.9
|
25.0
|
L
 -4.7%
H
23.6
26.6
|
L
 -4.7%
H
23.6
28.5
|
L
 11.2%
H
21.9
28.5
|
L
 17.9%
H
18.5
28.5
|
L
 -32.5%
H
12.2
41.3
|
L
 19.3%
H
12.2
41.3
|
L
 33.9%
H
12.2
41.3
|
L
H
10
134
|
ANI Pharmaceuticals Inc |
|
1,386.3
|
64.0
|
L
 -0.3%
H
63.4
66.4
|
L
 -3.5%
H
63.4
68.2
|
L
 -2.2%
H
63.2
68.6
|
L
 -9.5%
H
56.7
77
|
L
 0.8%
H
52.5
77
|
L
 86.9%
H
30.5
77
|
L
 116.5%
H
22.3
77
|
L
 -7.2%
H
22.3
87.0
|
Anixa Biosciences Inc |
|
101.8
|
3.2
|
L
 1.9%
H
3.1
3.3
|
L
 -5.4%
H
3.1
3.5
|
L
 -1.9%
H
3.1
3.5
|
L
 14.9%
H
2.5
3.8
|
L
 3.6%
H
2.1
4.2
|
L
 -16.8%
H
2.1
6.5
|
L
 18.4%
H
1.7
8.1
|
L
 -40.4%
H
0.6
8.1
|
AN2 Therapeutics Inc |
|
32.3
|
1.1
|
L
 -0.9%
H
1.1
1.1
|
L
 -3.6%
H
1.1
1.2
|
L
 -0.9%
H
1.1
1.2
|
L
 -12.3%
H
1.0
1.3
|
L
 -58.0%
H
0.9
2.7
|
L
 -87.5%
H
0.9
22.5
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
Applied Dna Sciences Inc |
|
2.5
|
4.8
|
L
 -1.4%
H
4.8
5.0
|
L
 -7.3%
H
4.8
6.0
|
L
 -0.2%
H
4.4
6.0
|
L
 -64.3%
H
4.4
14.0
|
L
 -98.5%
H
0.7
2655
|
L
 -100.0%
H
0.7
110250
|
L
 -100.0%
H
0.7
204600
|
L
 -100.0%
H
0.7
5820000
|
Aptevo Therapeutics Inc |
|
9.4
|
2.9
|
L
 2.1%
H
2.9
3.0
|
L
 -6.7%
H
2.8
3.3
|
L
 -5.2%
H
2.8
3.3
|
L
 -74.2%
H
2.8
14.3
|
L
 -99.1%
H
2.8
381.5
|
L
 -100.0%
H
2.8
234432
|
L
 -100.0%
H
2.8
1953600
|
L
H
2.8
3778913.6
|
AquaBounty Technologies Inc |
|
2.7
|
0.7
|
L
 -5.3%
H
0.7
0.8
|
L
 -9.0%
H
0.7
0.8
|
L
 -4.1%
H
0.7
0.9
|
L
 4.4%
H
0.6
1.0
|
L
 -59.0%
H
0.5
1.8
|
L
 -97.6%
H
0.5
32.8
|
L
 -99.0%
H
0.5
266.4
|
L
H
0.5
610
|
Arvinas Inc |
|
553.3
|
7.6
|
L
 1.3%
H
7.6
8.2
|
L
H
7.4
8.2
|
L
 0.5%
H
7.3
8.3
|
L
 -19.1%
H
5.9
9.7
|
L
 -72.7%
H
5.9
30.0
|
L
 -85.7%
H
5.9
58.6
|
L
 -77.0%
H
5.9
108.5
|
L
H
5.9
108.5
|
Arrowhead Pharmaceuticals ... |
|
2,168.2
|
15.7
|
L
 -1.4%
H
15.5
16.5
|
L
 5.0%
H
15.1
16.7
|
L
 -2.4%
H
14.3
19.3
|
L
 16.6%
H
12.4
19.3
|
L
 -45.2%
H
9.6
29.5
|
L
 -63.1%
H
9.6
48.5
|
L
 -64.6%
H
9.6
93.7
|
L
 154.0%
H
1.2
93.7
|
Athira Pharma Inc |
|
14.1
|
0.4
|
L
 -7.7%
H
0.3
0.4
|
L
 -23.4%
H
0.3
0.5
|
L
 20%
H
0.3
0.5
|
L
 20%
H
0.2
0.5
|
L
 -89.5%
H
0.2
3.7
|
L
 -89.7%
H
0.2
4.4
|
L
H
0.2
34.8
|
L
H
0.2
34.8
|
Aurinia Pharmaceuticals Inc |
|
1,222.7
|
9.1
|
L
 1.2%
H
8.8
9.4
|
L
 1.9%
H
8.8
9.4
|
L
 4.8%
H
7.3
9.4
|
L
 11.5%
H
7.3
9.4
|
L
 59.3%
H
5.2
10.7
|
L
 10.6%
H
4.1
12.4
|
L
 -31.4%
H
4.1
34.0
|
L
 145.3%
H
1.4
34.0
|
Aura Biosciences Inc |
|
408.6
|
6.6
|
L
 -3.0%
H
6.5
7.0
|
L
 -2.7%
H
6.5
7.5
|
L
 4.9%
H
6.0
7.5
|
L
 18.5%
H
4.3
7.5
|
L
 -33.8%
H
4.3
12.4
|
L
 -53.8%
H
4.3
24.8
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
Tectonic Therapeutic Inc. |
|
420.5
|
22.5
|
L
 0.9%
H
22.1
23.3
|
L
 1.4%
H
22.0
23.9
|
L
 13.7%
H
19.1
24.2
|
L
 11.4%
H
17.6
25.8
|
L
 24.2%
H
13.7
61.1
|
L
 106.2%
H
1.4
61.1
|
L
 -89.5%
H
1.4
240.8
|
L
H
1.4
644.4
|
Jade Biosciences Inc |
|
221.8
|
6.9
|
L
 -8.6%
H
6.7
7.7
|
L
 -23.4%
H
6.7
9.1
|
L
 -25.1%
H
6.7
11.3
|
L
 -32.2%
H
6.6
13.5
|
L
 -89.6%
H
6.6
105
|
L
 -99.1%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
Anavex Life Sciences Corpo... |
|
954.1
|
11.2
|
L
 -1.7%
H
10.9
11.6
|
L
H
10.9
14.0
|
L
 17.8%
H
9.1
14.0
|
L
 16.0%
H
7.2
14.0
|
L
 58.7%
H
4.9
14.4
|
L
 8.9%
H
3.3
15.2
|
L
 149.3%
H
3.3
31.5
|
L
 254.6%
H
1.3
31.5
|
Axsome Therapeutics Inc |
|
4,985.7
|
101.3
|
L
 0.9%
H
100.6
104.0
|
L
 -1.3%
H
99.4
107.0
|
L
 -2.0%
H
99.4
114.7
|
L
 -7.9%
H
99.4
120
|
L
 20.3%
H
72.2
139.1
|
L
 162.4%
H
35.2
139.1
|
L
 36.3%
H
19.4
139.1
|
L
H
1.9
139.1
|
Aziyo Biologics Inc - Ordi... |
|
-
|
2.0
|
L
 6.5%
H
1.8
2.1
|
L
 -6.7%
H
1.8
2.2
|
L
 -6.7%
H
1.8
2.6
|
L
 14.0%
H
1.6
2.6
|
L
 14.0%
H
1.6
2.6
|
L
 -70.1%
H
1.1
9.0
|
L
H
1.1
18.2
|
L
H
1.1
18.2
|
Adaptimmune Therapeutics P... |
|
26.5
|
0.1
|
L
H
0.1
0.1
|
L
 -63.0%
H
0.1
0.4
|
L
 -58.3%
H
0.1
0.4
|
L
 -61.5%
H
0.1
0.4
|
L
 -92.7%
H
0.1
1.5
|
L
 -94.6%
H
0.1
2.7
|
L
 -98.9%
H
0.1
10.9
|
L
 -99.4%
H
0.1
16.3
|
Akari Therapeutics Plc - ADR |
|
32.5
|
1.0
|
L
 -6.5%
H
1.0
1.1
|
L
 -10.6%
H
1.0
1.2
|
L
 -12.9%
H
1.0
1.2
|
L
 -26.3%
H
1.0
1.5
|
L
 -76.5%
H
0.9
4.2
|
L
 -95.6%
H
0.9
32.2
|
L
 -97.4%
H
0.9
84.2
|
L
 -99.1%
H
0.9
934
|
Autolus Therapeutics plc -... |
|
662.7
|
2.5
|
L
 2.9%
H
2.4
2.6
|
L
 -4.6%
H
2.3
2.7
|
L
 7.8%
H
2.2
2.7
|
L
 90.1%
H
1.2
2.7
|
L
 -46.2%
H
1.1
5
|
L
 -10.8%
H
1.1
7.5
|
L
 -81.1%
H
1.1
16.8
|
L
H
1.1
53.2
|
BridgeBio Pharma Inc |
|
8,662.4
|
45.6
|
L
 -1.5%
H
45.1
46.8
|
L
 -0.3%
H
45.1
47.1
|
L
 1.7%
H
41.8
48.7
|
L
 25.3%
H
31.8
48.7
|
L
 73.7%
H
21.7
48.7
|
L
 426.8%
H
6.6
48.7
|
L
 57.4%
H
5.0
73.5
|
L
H
5.0
73.5
|
BioAtla Inc |
|
21.0
|
0.4
|
L
 2.9%
H
0.4
0.4
|
L
 5.9%
H
0.3
0.4
|
L
 -5.3%
H
0.3
0.4
|
L
 -28%
H
0.3
0.6
|
L
 -78.2%
H
0.2
2.5
|
L
 -89.4%
H
0.2
12.2
|
L
H
0.2
76.6
|
L
H
0.2
76.6
|
BioCardia Inc. |
|
12.1
|
2.2
|
L
 -1.4%
H
2.2
2.2
|
L
 -4.8%
H
2.2
2.4
|
L
 1.9%
H
2.0
2.5
|
L
 -28.2%
H
1.8
3.2
|
L
 -30.9%
H
1.6
4.7
|
L
 -89.9%
H
1.6
43.8
|
L
 -94.0%
H
1.6
129
|
L
 -98.5%
H
1.6
2073.6
|
Biocryst Pharmaceuticals Inc. |
|
1,720.0
|
8.2
|
L
 1.6%
H
8.1
8.4
|
L
 -5.0%
H
8.0
8.7
|
L
 -12.2%
H
8.0
9.5
|
L
 -2.6%
H
8.0
11.3
|
L
 9.3%
H
6.0
11.3
|
L
 -25.4%
H
4.0
15.4
|
L
 94.8%
H
3.3
20.0
|
L
 -46.1%
H
1.4
20.0
|
BriaCell Therapeutics Corp |
|
14.0
|
0.8
|
L
H
0.8
0.8
|
L
H
0.8
0.8
|
L
 -73.0%
H
0.7
3.1
|
L
 -82.6%
H
0.7
4.6
|
L
 8.1%
H
0.4
9.8
|
L
 -87.6%
H
0.4
9.8
|
L
 -88.8%
H
0.4
12.4
|
L
 -98.6%
H
0.4
92.1
|
Black Diamond Therapeutics... |
|
160.4
|
2.8
|
L
 1.4%
H
2.8
3.0
|
L
 -11.6%
H
2.7
3.3
|
L
 20%
H
2.4
3.3
|
L
 76.3%
H
1.5
3.3
|
L
 -53.2%
H
1.2
6.8
|
L
 -19.4%
H
1.2
7.7
|
L
 -90.1%
H
1.2
37.8
|
L
H
1.2
46.3
|
Beam Therapeutics Inc |
|
2,026.2
|
20.2
|
L
 1.1%
H
20
21.4
|
L
 -6.5%
H
19.9
22.8
|
L
 19.9%
H
16.6
22.8
|
L
 2.2%
H
15.4
22.8
|
L
 -37.1%
H
13.5
35.3
|
L
 -68.0%
H
13.5
73.3
|
L
 -2.0%
H
13.5
138.5
|
L
H
13
138.5
|
Biogen |
|
18,556.3
|
126.6
|
L
 -1.0%
H
126.0
129.8
|
L
 -1.0%
H
126.0
133.1
|
L
 0.4%
H
121.1
137.8
|
L
 5.4%
H
115.3
137.8
|
L
 -40.9%
H
110.0
219.4
|
L
 -41.1%
H
110.0
319.8
|
L
 -54.3%
H
110.0
468.6
|
L
 -56.1%
H
110.0
468.6
|
BioVie Inc |
|
12.4
|
6.7
|
L
 -4.2%
H
6.6
7.1
|
L
 -18.6%
H
6.6
8.4
|
L
 -34.0%
H
6.5
10.3
|
L
 -19.4%
H
6.5
13.2
|
L
 -83.7%
H
6.2
75
|
L
 -96.9%
H
6.2
1438
|
L
 -99.5%
H
6.2
4609.8
|
L
 -99.7%
H
6.2
5625
|
Biomarin Pharmaceutical In... |
|
11,278.3
|
58.8
|
L
 1%
H
58.3
59.6
|
L
 -0.7%
H
57.6
60.4
|
L
 6.6%
H
54.4
60.4
|
L
 -7.1%
H
53.7
65.4
|
L
 -30.1%
H
52.9
94.9
|
L
 -31.7%
H
52.9
117.8
|
L
 -51.2%
H
52.9
124.5
|
L
 -59.3%
H
52.9
148.3
|
Bionano Genomics Inc |
|
10.2
|
3.0
|
L
 -2.0%
H
3.0
3.1
|
L
 -14.5%
H
3.0
3.6
|
L
 -8.2%
H
3.0
3.6
|
L
 -27.2%
H
3.0
5.0
|
L
 379.4%
H
0.1
11.6
|
L
 -83.8%
H
0.1
43.5
|
L
 -59.5%
H
0.1
156.9
|
L
H
0.1
156.9
|
Benitec Biopharma Inc |
|
295.3
|
11.3
|
L
 1.8%
H
11.1
11.7
|
L
 -0.1%
H
10.7
12.3
|
L
 -0.9%
H
10.7
14.2
|
L
 -17.8%
H
10.7
17.2
|
L
 23.6%
H
7.1
17.2
|
L
 -26.4%
H
1.9
18.0
|
L
 -91.4%
H
1.9
178.3
|
L
 -99.7%
H
1.9
3547.1
|
Bon Natural Life Ltd |
|
5.0
|
1.3
|
L
 -3.7%
H
1.3
1.4
|
L
 -8.3%
H
1.3
1.5
|
L
 4.8%
H
1.2
1.6
|
L
 -27.5%
H
1.1
2.8
|
L
 -97.4%
H
1.1
73.8
|
L
 -99.7%
H
1.1
1075
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
23052.5
|
BioXcel Therapeutics Inc |
|
8.7
|
1.4
|
L
 -10.1%
H
1.4
1.6
|
L
 -20.6%
H
1.4
1.9
|
L
 -19.2%
H
1.4
2.3
|
L
 -28.1%
H
1.2
2.3
|
L
 22.2%
H
0.2
6.8
|
L
 -90.7%
H
0.2
34.1
|
L
 -97.0%
H
0.2
67.7
|
L
H
0.2
71.5
|
Bicycle Therapeutics Plc -... |
|
589.4
|
8.5
|
L
 -0.1%
H
8.5
8.9
|
L
 1.7%
H
8.4
9.2
|
L
 17.5%
H
6.9
9.2
|
L
 3.7%
H
6.9
9.6
|
L
 -64.2%
H
6.1
28.7
|
L
 -63.9%
H
6.1
33.5
|
L
 -47.6%
H
6.1
62.1
|
L
H
6.1
62.1
|
BioNTech SE - ADR |
|
26,455.5
|
110.1
|
L
 -1.3%
H
109.5
113.3
|
L
 -1.3%
H
109.5
115.5
|
L
 3.1%
H
105.3
115.5
|
L
 5.8%
H
89.8
122.9
|
L
 27.1%
H
76.5
131.5
|
L
 -33.4%
H
76.5
189.0
|
L
 33.4%
H
54.1
464
|
L
H
12.5
464
|
Cabaletta Bio Inc |
|
140.3
|
1.6
|
L
 -0.6%
H
1.6
1.7
|
L
 -1.3%
H
1.6
1.7
|
L
 -0.6%
H
1.4
1.8
|
L
 21.9%
H
1.1
2.6
|
L
 -78.0%
H
1.0
7.3
|
L
 32.2%
H
0.6
26.4
|
L
 -87.1%
H
0.6
26.4
|
L
H
0.6
26.4
|
CalciMedica Inc |
|
51.4
|
3.7
|
L
 -2.7%
H
3.6
3.8
|
L
 -2.7%
H
3.4
4.3
|
L
 157.3%
H
1.4
4.3
|
L
 142.1%
H
1.4
4.3
|
L
 -11.3%
H
1.4
6.0
|
L
 -72.6%
H
1
20.2
|
L
H
1
530.3
|
L
H
1
530.3
|
Tvardi Therapeutics Inc. |
|
240.5
|
25.7
|
L
 -1.1%
H
25.1
27.1
|
L
 1.3%
H
24.3
28.8
|
L
 4.4%
H
21.1
32.0
|
L
 11.7%
H
21.1
34.3
|
L
 98.2%
H
8.1
34.3
|
L
 -91.8%
H
8.1
467.3
|
L
 -95.8%
H
8.1
1067.3
|
L
 -96.3%
H
8.1
1067.3
|
Carisma Therapeutics Inc |
|
14.2
|
0.3
|
L
H
0.3
0.4
|
L
 -12.8%
H
0.3
0.4
|
L
 -15%
H
0.3
0.5
|
L
 70%
H
0.1
1.3
|
L
 -69.6%
H
0.1
1.3
|
L
 -97.8%
H
0.1
16.2
|
L
 -98.3%
H
0.1
120.8
|
L
 -99.4%
H
0.1
160
|
Crescent Biopharma Inc. |
|
-
|
12.6
|
L
 2.4%
H
12.3
13.1
|
L
 -3.4%
H
12.1
13.5
|
L
 -20.8%
H
11.5
17.4
|
L
 11.0%
H
7.6
21.4
|
L
 11.0%
H
7.6
21.4
|
L
 195.1%
H
2.8
21.4
|
L
 0.7%
H
0.9
21.4
|
L
 -97.4%
H
0.9
790.9
|
C4 Therapeutics Inc |
|
153.4
|
2.2
|
L
 -4%
H
2.1
2.3
|
L
 -2.7%
H
2.1
2.5
|
L
 54.3%
H
1.4
2.7
|
L
 36.7%
H
1.2
2.7
|
L
 -67.0%
H
1.1
7.4
|
L
 -77.6%
H
1.1
13.2
|
L
H
1.1
51.2
|
L
H
1.1
51.2
|
Compugen Ltd |
|
134.7
|
1.4
|
L
 -2.7%
H
1.4
1.5
|
L
 -7.1%
H
1.4
1.6
|
L
 -13.3%
H
1.4
1.8
|
L
 2.9%
H
1.2
1.9
|
L
 -15.8%
H
1.1
2.7
|
L
 -10.6%
H
0.5
3.0
|
L
 -89.9%
H
0.5
19.9
|
L
 -76.9%
H
0.5
19.9
|
Cognition Therapeutics Inc |
|
38.4
|
0.6
|
L
 -7.5%
H
0.6
0.7
|
L
 -20.5%
H
0.6
0.9
|
L
 106.7%
H
0.3
1.0
|
L
 47.6%
H
0.2
1.0
|
L
 -53.4%
H
0.2
1.3
|
L
 -67.2%
H
0.2
6.3
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
Co-Diagnostics Inc |
|
8.8
|
0.3
|
L
H
0.3
0.3
|
L
 -10.3%
H
0.3
0.3
|
L
H
0.2
0.3
|
L
 -27.8%
H
0.2
0.5
|
L
 -77.0%
H
0.2
2.2
|
L
 -96.0%
H
0.2
7.1
|
L
 -98.8%
H
0.2
31.0
|
L
H
0.2
31.0
|
Coeptis Therapeutics Holdi... |
|
38.4
|
10.9
|
L
 -2.1%
H
10.6
11.2
|
L
 0.1%
H
10.6
12.8
|
L
 40.4%
H
7.2
12.8
|
L
 10.1%
H
6.8
12.8
|
L
 112.5%
H
2.3
13.7
|
L
 7.7%
H
2.3
242.6
|
L
H
2.3
242.6
|
L
H
2.3
242.6
|
Cogent Biosciences Inc |
|
1,607.4
|
11.5
|
L
 -2.6%
H
11.5
12.3
|
L
 -7.4%
H
11.5
12.8
|
L
 62.4%
H
7.1
13.0
|
L
 129.7%
H
4.6
13.0
|
L
 22.8%
H
3.7
13.0
|
L
 4.0%
H
3.7
18.1
|
L
 11.7%
H
3.7
18.1
|
L
H
1.2
70.6
|
Caribou Biosciences Inc |
|
190.7
|
2.1
|
L
 4.6%
H
2
2.1
|
L
 -13.5%
H
1.9
2.7
|
L
 62.7%
H
1.2
2.7
|
L
 141.2%
H
0.7
2.7
|
L
 -13.1%
H
0.7
3
|
L
 -74.8%
H
0.7
13.2
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
Cardiol Therapeutics Inc -... |
|
122.3
|
1.5
|
L
 1.4%
H
1.4
1.5
|
L
 5.7%
H
1.3
1.6
|
L
 5.0%
H
1.1
1.6
|
L
 28.7%
H
1.0
1.6
|
L
 -34.2%
H
0.8
2.6
|
L
 12.1%
H
0.5
3.1
|
L
 -40.8%
H
0.5
5.3
|
L
H
0.5
8.5
|
Curis Inc |
|
20.5
|
1.7
|
L
 -2.8%
H
1.7
1.8
|
L
 -6.0%
H
1.7
1.9
|
L
 -21.2%
H
1.5
2.5
|
L
 -5.5%
H
1.5
3.1
|
L
 -71.7%
H
1.0
8.3
|
L
 -91.3%
H
1.0
35.4
|
L
 -93.0%
H
1.0
348
|
L
 -99.5%
H
1.0
372
|
CorMedix Inc |
|
858.9
|
11.5
|
L
 -0.9%
H
11.4
12.0
|
L
 4.3%
H
11.1
12.1
|
L
 -7.7%
H
10.7
12.7
|
L
 26.5%
H
8.7
17.4
|
L
 146.6%
H
3.6
17.4
|
L
 115.7%
H
2.6
17.4
|
L
 146.1%
H
2.6
18.8
|
L
 -28.5%
H
0.9
22.7
|
CRISPR Therapeutics AG |
|
4,981.5
|
57.7
|
L
 -2.3%
H
56.5
61.4
|
L
 -12.5%
H
56.5
69.6
|
L
 21.5%
H
46.6
71.1
|
L
 54.2%
H
33.0
71.1
|
L
 -1.4%
H
30.0
71.1
|
L
 -23.1%
H
30.0
91.1
|
L
 -32.6%
H
30.0
220.2
|
L
H
11.6
220.2
|
Champions Oncology Inc |
|
88.3
|
6.4
|
L
 -0.2%
H
6.2
6.6
|
L
 -18.2%
H
6.1
8.1
|
L
 -17.4%
H
6.1
9.6
|
L
 -14.8%
H
5.6
9.6
|
L
 28.7%
H
3.6
12.0
|
L
 -26.0%
H
3.6
12.0
|
L
 -29.2%
H
3.6
14.7
|
L
 22.8%
H
1.1
17.9
|
Cue Biopharma Inc |
|
61.8
|
0.8
|
L
H
0.8
0.9
|
L
 -8.9%
H
0.8
0.9
|
L
 10.8%
H
0.7
1.0
|
L
 7.9%
H
0.5
1.0
|
L
 26.2%
H
0.5
2.0
|
L
 -69.9%
H
0.5
5.1
|
L
 -95.7%
H
0.5
22.5
|
L
H
0.5
31.7
|
Cadrenal Therapeutics Inc |
|
20.7
|
10.5
|
L
 -3.0%
H
10.5
10.9
|
L
 -2.5%
H
10.5
12.0
|
L
 1.0%
H
10.5
13.7
|
L
 -37.2%
H
10
17
|
L
 2242.2%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
Chemomab Therapeutics Ltd ... |
|
20.7
|
1.1
|
L
 -0.9%
H
1.1
1.1
|
L
 -3.6%
H
1.1
1.2
|
L
 -7.7%
H
1.1
1.2
|
L
 -15.6%
H
1.1
1.5
|
L
 -8.5%
H
0.9
2.6
|
L
 -64.6%
H
0.4
5.4
|
L
 -99.5%
H
0.4
2700.8
|
L
H
0.4
2944
|
Compass Pathways Plc - ADR |
|
368.6
|
3.9
|
L
 -8.2%
H
3.9
4.4
|
L
 -10.9%
H
3.9
4.7
|
L
 42.2%
H
2.7
4.7
|
L
 4.5%
H
2.3
5.2
|
L
 -50.5%
H
2.3
8.5
|
L
 -74.7%
H
2.3
21.5
|
L
H
2.3
61.7
|
L
H
2.3
61.7
|
Denali Therapeutics Inc |
|
1,985.9
|
13.7
|
L
 0.4%
H
13.6
14.7
|
L
 -1.4%
H
13.5
14.7
|
L
 -3.1%
H
13.5
15.4
|
L
 -17.2%
H
12.9
17.0
|
L
 -43.9%
H
10.6
33.3
|
L
 -59.8%
H
10.6
39.4
|
L
 -42.3%
H
10.6
93.9
|
L
H
10.6
93.9
|
Dominari Holdings Inc |
|
64.4
|
4.4
|
L
 -9.3%
H
4.4
4.9
|
L
 -15.9%
H
4.4
5.4
|
L
 -20.7%
H
4.4
5.9
|
L
 -5.8%
H
4.0
6.5
|
L
 152.9%
H
0.8
13.6
|
L
 -24.4%
H
0.8
13.6
|
L
 -77.3%
H
0.8
43.4
|
L
 -98.4%
H
0.8
850.9
|
DarioHealth Corp |
|
25.8
|
0.6
|
L
 7.4%
H
0.5
0.6
|
L
 -17.1%
H
0.5
0.7
|
L
 -13.4%
H
0.5
0.7
|
L
 -19.4%
H
0.5
0.8
|
L
 -48.7%
H
0.5
1.6
|
L
 -90.5%
H
0.5
7.3
|
L
 -92.9%
H
0.5
31.9
|
L
 -99.5%
H
0.5
233.5
|
Bright Minds Biosciences Inc |
|
239.1
|
33.8
|
L
 -3.1%
H
33.2
36.5
|
L
 27.7%
H
26.7
37.6
|
L
 45.0%
H
24.0
37.6
|
L
 9.3%
H
23.2
37.6
|
L
 2834.8%
H
0.9
79.0
|
L
 577.7%
H
0.9
79.0
|
L
H
0.9
79.0
|
L
H
0.9
79.0
|
Design Therapeutics Inc |
|
228.8
|
4.0
|
L
 1.3%
H
4.0
4.2
|
L
 -5.2%
H
3.8
4.4
|
L
 12.9%
H
3.3
4.4
|
L
 -8.2%
H
3.1
5.0
|
L
 -19.4%
H
2.6
7.8
|
L
 -79.5%
H
1.9
26.3
|
L
H
1.9
50.5
|
L
H
1.9
50.5
|
Precision Biosciences Inc |
|
53.2
|
4.8
|
L
 -1.8%
H
4.7
5.1
|
L
 -1.2%
H
4.5
5.3
|
L
 11.6%
H
4.1
5.3
|
L
 -8.2%
H
4.0
6.0
|
L
 -52%
H
3.6
11.1
|
L
 226.5%
H
0.3
19.4
|
L
 -33.3%
H
0.3
19.4
|
L
H
0.3
23.7
|
Dynavax Technologies Corp. |
|
1,341.3
|
11.2
|
L
 -0.2%
H
11.1
11.4
|
L
 -0.1%
H
11.1
11.5
|
L
 12.7%
H
9.8
11.5
|
L
 -3.3%
H
9.2
11.8
|
L
 -3.5%
H
9.2
14.6
|
L
 -22.3%
H
9.2
17.5
|
L
 40.2%
H
3.6
21.4
|
L
 -62.3%
H
1.8
32.5
|
Dyne Therapeutics Inc |
|
1,128.5
|
9.9
|
L
 7.7%
H
9.3
10.1
|
L
 7.6%
H
8.9
10.2
|
L
 3.6%
H
8.1
10.2
|
L
 -15.4%
H
8.1
15.2
|
L
 -76.9%
H
6.4
47.5
|
L
 -5.5%
H
6.4
47.5
|
L
H
4.3
47.5
|
L
H
4.3
47.5
|
Editas Medicine Inc |
|
211.0
|
2.5
|
L
 -2.7%
H
2.5
2.7
|
L
 -25%
H
2.5
3.6
|
L
 10.5%
H
2.1
3.6
|
L
 62.6%
H
1.3
3.6
|
L
 -53.3%
H
0.9
5.7
|
L
 -84.2%
H
0.9
20.0
|
L
 -91.6%
H
0.9
100.0
|
L
H
0.9
100.0
|
Elicio Therapeutics Inc. |
|
158.7
|
9.9
|
L
 -1.8%
H
9.8
10.8
|
L
 6.4%
H
9.3
10.8
|
L
 25.6%
H
7.6
10.8
|
L
 106.2%
H
4.9
10.8
|
L
 101.2%
H
3.7
10.8
|
L
 -8.1%
H
3.0
24.4
|
L
H
3.0
263
|
L
H
3.0
263
|
Enliven Therapeutics Inc |
|
1,139.7
|
19.3
|
L
 -3.7%
H
19.0
20.4
|
L
 -10.4%
H
19.0
22.8
|
L
 -6.6%
H
19.0
24.4
|
L
 3.6%
H
15.8
24.4
|
L
 -27.3%
H
13.3
30.0
|
L
 312.8%
H
4.4
30.0
|
L
 -75.9%
H
3.9
144
|
L
H
3.9
250.8
|
Climb Bio Inc. |
|
102.7
|
1.5
|
L
 0.7%
H
1.5
1.6
|
L
 7.8%
H
1.4
1.7
|
L
 28.8%
H
1.2
1.7
|
L
 20.6%
H
1.1
1.7
|
L
 -82.1%
H
1.1
8.9
|
L
 -52.2%
H
1.1
11.6
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
Enlivex Therapeutics Ltd |
|
36.7
|
1.5
|
L
 8.5%
H
1.4
1.7
|
L
 30.5%
H
1.1
1.7
|
L
 28.3%
H
1.1
1.7
|
L
 46.7%
H
0.9
1.7
|
L
 12.4%
H
0.8
1.8
|
L
 -63.8%
H
0.8
6.2
|
L
 -72.9%
H
0.8
29.4
|
L
 -99.4%
H
0.8
318
|
Enochian Biosciences Inc |
|
-
|
0.3
|
L
 -3.5%
H
0.3
0.3
|
L
 -9.7%
H
0.3
0.4
|
L
 -3.5%
H
0.3
0.4
|
L
 -12.5%
H
0.3
0.5
|
L
 -12.5%
H
0.3
0.5
|
L
 -87.8%
H
0.3
3.0
|
L
 -92.6%
H
0.3
13.8
|
L
 -94.2%
H
0.3
13.8
|
Ensysce Biosciences Inc |
|
4.9
|
2.1
|
L
 -5.5%
H
2.0
2.2
|
L
 -5.5%
H
2.0
2.4
|
L
 -7.1%
H
2.0
2.4
|
L
 -31.8%
H
2.0
3.2
|
L
 362.2%
H
0.1
9.9
|
L
 -98.3%
H
0.1
180
|
L
 -99.9%
H
0.1
5757.6
|
L
H
0.1
5757.6
|
Equillium Inc |
|
13.6
|
0.4
|
L
 -5%
H
0.4
0.4
|
L
 -2.6%
H
0.4
0.5
|
L
 22.6%
H
0.3
0.5
|
L
 -13.6%
H
0.3
0.5
|
L
 -51.9%
H
0.3
1.5
|
L
 -82.8%
H
0.3
3.3
|
L
 -96.7%
H
0.3
12.3
|
L
H
0.3
27.1
|
Edgewise Therapeutics Inc |
|
1,497.0
|
14.2
|
L
 2.0%
H
14.1
15.3
|
L
 5.1%
H
13.6
15.3
|
L
 8.1%
H
12.5
15.3
|
L
 -8.0%
H
12.2
17.3
|
L
 -21.1%
H
10.6
38.1
|
L
 47.2%
H
5.1
38.1
|
L
H
5.1
40.5
|
L
H
5.1
40.5
|
Evaxion Biotech A/S - ADR |
|
17.5
|
2.8
|
L
 -5.8%
H
2.8
3.0
|
L
 6.1%
H
2.5
3.1
|
L
 13.1%
H
2.3
3.1
|
L
 84.7%
H
1.4
3.2
|
L
 -8.3%
H
0.8
9.8
|
L
 -90.9%
H
0.8
35.2
|
L
H
0.8
250.4
|
L
H
0.8
250.4
|
Fate Therapeutics Inc |
|
130.7
|
1.1
|
L
 -2.6%
H
1.1
1.2
|
L
 -8.1%
H
1.1
1.4
|
L
 9.6%
H
1.1
1.4
|
L
 -2.6%
H
0.9
1.8
|
L
 -78.9%
H
0.7
5.8
|
L
 -96.3%
H
0.7
37.1
|
L
 -96.3%
H
0.7
121.2
|
L
 -84.0%
H
0.7
121.2
|
Forte Biosciences Inc |
|
124.3
|
10.2
|
L
 -4.5%
H
10.1
11.0
|
L
 -2.4%
H
10.1
12.0
|
L
 -16.9%
H
9.1
14.5
|
L
 38.7%
H
6.1
19.6
|
L
 -27.1%
H
4.1
28
|
L
 -67.2%
H
4.1
34.5
|
L
 -98.1%
H
4.1
1349.8
|
L
H
0.0
1349.8
|
4D Molecular Therapeutics Inc |
|
204.3
|
4.4
|
L
 1.2%
H
4.3
4.6
|
L
 -2%
H
4.3
4.8
|
L
 14.8%
H
3.7
4.8
|
L
 36.1%
H
3
5.1
|
L
 -74.2%
H
2.2
18.1
|
L
 -53.1%
H
2.2
36.3
|
L
H
2.2
55.1
|
L
H
2.2
55.1
|
Foghorn Therapeutics Inc |
|
303.8
|
5.5
|
L
 -7.6%
H
5.4
6.2
|
L
 -14.0%
H
5.4
6.8
|
L
 12.6%
H
4.6
6.8
|
L
 28.2%
H
3.6
6.8
|
L
 -20.3%
H
2.9
10.2
|
L
 -62.7%
H
2.7
18.1
|
L
H
2.7
28.3
|
L
H
2.7
28.3
|
Frequency Therapeutics Inc |
|
-
|
16.3
|
L
 7.3%
H
15.5
16.8
|
L
 14.6%
H
14.2
17.8
|
L
 35.2%
H
11.8
17.8
|
L
 7.6%
H
10.3
17.8
|
L
 7.6%
H
10.3
17.8
|
L
 -83.7%
H
9.2
279.5
|
L
 -98.5%
H
9.2
2918.5
|
L
H
9.2
2918.5
|
First Wave BioPharma Inc |
|
0.7
|
0.5
|
L
 -2.1%
H
0.5
0.5
|
L
 -8%
H
0.5
0.5
|
L
 21.1%
H
0.4
0.6
|
L
 9.5%
H
0.4
0.7
|
L
 9.5%
H
0.4
0.7
|
L
 -99.9%
H
0.4
756.1
|
L
 -100.0%
H
0.4
110458.7
|
L
H
0.4
235200
|
Galectin Therapeutics Inc |
|
227.8
|
3.6
|
L
 9.1%
H
3.3
3.8
|
L
 25.9%
H
2.8
3.8
|
L
 54.5%
H
2.1
3.8
|
L
 188%
H
1.2
3.9
|
L
 40.1%
H
0.7
3.9
|
L
 59.3%
H
0.7
4.3
|
L
 32.4%
H
0.7
5.7
|
L
 34.8%
H
0.5
9.5
|
Gain Therapeutics Inc |
|
51.9
|
1.5
|
L
 -4.5%
H
1.5
1.6
|
L
 -7.4%
H
1.5
1.7
|
L
 -23.9%
H
1.5
2.0
|
L
 -20.2%
H
1.5
2.3
|
L
 32.7%
H
0.9
3.2
|
L
 -62.3%
H
0.9
6.2
|
L
H
0.9
17.9
|
L
H
0.9
17.9
|
CytoMed Therapeutics Ltd |
|
21.8
|
1.9
|
L
 -2.6%
H
1.8
1.9
|
L
 -6.4%
H
1.8
2.0
|
L
 -18.9%
H
1.8
2.4
|
L
 -20.6%
H
1.8
2.6
|
L
 11.2%
H
1.2
4.1
|
L
H
1.2
9.3
|
L
H
1.2
9.3
|
L
H
1.2
9.3
|
Geron Corp. |
|
700.6
|
1.1
|
L
 -3.5%
H
1.1
1.2
|
L
 -14.1%
H
1.1
1.4
|
L
 -26.2%
H
1.1
1.5
|
L
 -20.3%
H
1.1
1.7
|
L
 -76.6%
H
1.1
4.9
|
L
 -42.1%
H
1.1
5.3
|
L
 -37.1%
H
1.0
5.3
|
L
 -73.1%
H
0.8
7.0
|
Gilead Sciences |
|
142,753.3
|
114.8
|
L
 0.5%
H
113.5
115.8
|
L
 4.2%
H
110.4
117.6
|
L
 3.7%
H
107.8
117.6
|
L
 10.1%
H
95.3
117.6
|
L
 47.6%
H
72.4
120.0
|
L
 92.1%
H
59.3
120.0
|
L
 57.2%
H
56.6
120.0
|
L
 -0.8%
H
56.6
120.4
|
Greenwich LifeSciences Inc |
|
150.4
|
11.3
|
L
 1.1%
H
11.1
11.7
|
L
 1.0%
H
11.1
11.7
|
L
 25.1%
H
9.0
12.5
|
L
 8.6%
H
8.6
12.5
|
L
 -27.4%
H
8.1
16.5
|
L
 39.1%
H
7.6
21.5
|
L
H
3.3
158.1
|
L
H
3.3
158.1
|
Monte Rosa Therapeutics Inc |
|
343.2
|
5.6
|
L
 6.1%
H
5.3
5.6
|
L
 -1.4%
H
5.2
6.1
|
L
 21.3%
H
4.4
6.3
|
L
 16.5%
H
3.5
6.3
|
L
 22.1%
H
3.5
12.4
|
L
 -38.5%
H
2.4
12.4
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
Geovax Labs Inc |
|
11.7
|
0.8
|
L
 1.3%
H
0.8
0.8
|
L
 -7.3%
H
0.7
0.9
|
L
 -20.8%
H
0.4
1.0
|
L
 -24%
H
0.4
1.4
|
L
 -67.0%
H
0.4
11.1
|
L
 -72.2%
H
0.3
11.1
|
L
 -95.4%
H
0.3
18.2
|
L
 -100.0%
H
0.3
1000000
|
Graphite Bio Inc |
|
1,791.4
|
30.8
|
L
 -2.9%
H
30.7
32.6
|
L
 -6.7%
H
30.7
34.9
|
L
 1.9%
H
28.8
36.0
|
L
 14.7%
H
25.9
36.0
|
L
 14.7%
H
25.9
36.0
|
L
 -80.1%
H
25.9
413
|
L
H
25.9
1666
|
L
H
25.9
1666
|
Galapagos NV - ADR |
|
2,192.4
|
33.3
|
L
 1.4%
H
32.9
33.5
|
L
 1.5%
H
28.8
33.9
|
L
 18.9%
H
27.8
33.9
|
L
 23.6%
H
24.7
33.9
|
L
 20.3%
H
22.4
33.9
|
L
 -34.6%
H
22.4
56.2
|
L
 -82.1%
H
22.4
195.7
|
L
 -41.3%
H
22.4
274.0
|
Halozyme Therapeutics Inc. |
|
7,403.1
|
60.1
|
L
 1.7%
H
59.1
60.4
|
L
 4.4%
H
57.3
60.4
|
L
 15.1%
H
51.1
60.4
|
L
 -1.2%
H
47.5
70.5
|
L
 8.3%
H
42.7
70.5
|
L
 22.9%
H
29.9
70.5
|
L
 125.4%
H
25.2
70.5
|
L
 156.4%
H
7.0
70.5
|
HCW Biologics Inc |
|
10.9
|
4.3
|
L
 -2.5%
H
4.1
4.4
|
L
 -0.5%
H
4.0
4.5
|
L
 -4.4%
H
3.6
4.9
|
L
 -42.8%
H
3.6
17.8
|
L
 -83.0%
H
0.2
100.8
|
L
 -95.5%
H
0.2
111.6
|
L
H
0.2
311
|
L
H
0.2
311
|
Hillstream BioPharma Inc |
|
15.5
|
1.3
|
L
 -1.5%
H
1.3
1.3
|
L
 -18.5%
H
1.3
1.7
|
L
 -26.7%
H
1.3
2.0
|
L
 -0.8%
H
1.3
2.0
|
L
 -0.8%
H
1.3
2.0
|
L
 -95.4%
H
1.3
132.8
|
L
H
1.3
132.8
|
L
H
1.3
132.8
|
HilleVax Inc |
|
104.7
|
2.1
|
L
 -1.0%
H
2.1
2.2
|
L
 -1.0%
H
2.1
2.2
|
L
 6.1%
H
1.9
2.2
|
L
 8.3%
H
1.8
2.2
|
L
 11.2%
H
1.3
2.2
|
L
 -84.5%
H
1.3
24.4
|
L
H
1.3
24.4
|
L
H
1.3
24.4
|
Hookipa Pharma Inc |
|
11.0
|
0.9
|
L
H
0.9
0.9
|
L
 -7.2%
H
0.9
1.0
|
L
 -28%
H
0.9
1.4
|
L
 7.1%
H
0.9
1.8
|
L
 -84.2%
H
0.7
6
|
L
 -93.4%
H
0.7
20.5
|
L
 -99.1%
H
0.7
200
|
L
H
0.7
200
|
Heron Therapeutics Inc |
|
273.1
|
1.8
|
L
 -3.2%
H
1.8
1.9
|
L
 -5.8%
H
1.8
2.0
|
L
 -16.4%
H
1.8
2.3
|
L
 -23.5%
H
1.7
2.6
|
L
 -38.9%
H
1.0
3.0
|
L
 -35.6%
H
0.5
5.6
|
L
 -89.4%
H
0.5
22.4
|
L
 -94.5%
H
0.5
42.9
|
Quantum BioPharma Ltd. - O... |
|
77.7
|
22.7
|
L
 1.2%
H
22.4
24.3
|
L
 3.9%
H
21.6
26.7
|
L
 4.6%
H
15.9
26.7
|
L
 231.5%
H
6.5
38.3
|
L
 173.9%
H
2.7
38.3
|
L
 -61.2%
H
2.7
136.5
|
L
 -90.7%
H
2.7
446.6
|
L
H
2.7
11431.9
|
Humacyte Inc |
|
376.9
|
2.4
|
L
 2.5%
H
2.3
2.5
|
L
 5.7%
H
2.3
2.8
|
L
 14.6%
H
2.1
2.8
|
L
 69.9%
H
1.2
2.9
|
L
 -69.0%
H
1.2
9.8
|
L
 -30.2%
H
1.2
10.0
|
L
H
1.2
17.5
|
L
H
1.2
17.5
|
Immucell Corp. |
|
58.4
|
6.5
|
L
 -0.5%
H
6.3
6.8
|
L
 -5.4%
H
6.3
7.3
|
L
 -4.3%
H
6.2
7.3
|
L
 18.5%
H
4.8
7.6
|
L
 61.5%
H
3.3
7.6
|
L
 -26.4%
H
3.3
9.6
|
L
 11.2%
H
3.3
13.2
|
L
 -39.1%
H
3.3
13.2
|
InflaRx N.V. |
|
59.6
|
0.9
|
L
 1.2%
H
0.9
1.0
|
L
 4.8%
H
0.8
1.0
|
L
 8.6%
H
0.8
1
|
L
 -39.3%
H
0.7
1.9
|
L
 -42.9%
H
0.7
2.8
|
L
 -67.9%
H
0.7
7.3
|
L
 -82.0%
H
0.7
7.3
|
L
H
0.7
53.1
|
ImageneBio Inc. |
|
177.4
|
15.3
|
L
 0.6%
H
15.1
15.8
|
L
 2.8%
H
15.1
18
|
L
 -6.3%
H
14.4
18
|
L
 -2.0%
H
12.5
18
|
L
 -25.9%
H
11.7
23.3
|
L
 -74.8%
H
11.7
91.7
|
L
H
11.7
451.3
|
L
H
11.7
451.3
|
Illumina Inc |
|
16,884.3
|
106.7
|
L
 -1.9%
H
105.7
109.6
|
L
 4.5%
H
102.8
111
|
L
 12.5%
H
92.3
111
|
L
 38.3%
H
73.9
111
|
L
 -12.3%
H
68.7
156.7
|
L
 -50.8%
H
68.7
248.9
|
L
 -72.3%
H
68.7
555.8
|
L
 -50.9%
H
68.7
555.8
|
Immunome Inc |
|
935.4
|
10.8
|
L
 1.4%
H
10.6
11.1
|
L
 -2.9%
H
10.3
11.7
|
L
 22.6%
H
8.0
11.7
|
L
 25.9%
H
7.2
11.7
|
L
 -31.8%
H
5.2
16.7
|
L
 177.1%
H
2.2
31.0
|
L
H
2.1
63.8
|
L
H
2.1
63.8
|
Imunon Inc |
|
16.1
|
7.6
|
L
 -3.1%
H
7.3
9.2
|
L
 -18.7%
H
6.5
9.2
|
L
 -31.4%
H
6.5
12.9
|
L
 -42.5%
H
5.6
47.4
|
L
 -57.4%
H
5.6
54.8
|
L
 -76.7%
H
5.6
54.8
|
L
 -96.9%
H
5.6
783
|
L
 -99.9%
H
5.6
8032.5
|
Immatics N.V |
|
812.0
|
6.7
|
L
 0.8%
H
6.6
6.8
|
L
 12.5%
H
6.0
6.8
|
L
 23.0%
H
5.2
6.8
|
L
 37.2%
H
3.9
6.8
|
L
 -44.7%
H
3.3
13.1
|
L
 -39.8%
H
3.3
13.8
|
L
 -36.9%
H
3.3
18.4
|
L
H
3.3
18.4
|
Immunovant Inc |
|
2,843.2
|
16.6
|
L
 -0.2%
H
16.3
17.1
|
L
 -7.4%
H
15.3
18.9
|
L
 3.2%
H
15.3
19.1
|
L
 9.2%
H
13.4
19.1
|
L
 -42.9%
H
12.7
34.5
|
L
 303.4%
H
3.9
45.6
|
L
 -29.2%
H
3.1
53.8
|
L
H
3.1
53.8
|
IN8bio Inc |
|
7.4
|
2.2
|
L
 -2.3%
H
2.1
2.3
|
L
 -9.3%
H
2.1
2.6
|
L
 0.9%
H
2.1
2.6
|
L
 1164.7%
H
0.1
4.2
|
L
 156.0%
H
0.1
4.2
|
L
 -15.4%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
Inhibrx Inc |
|
1,089.2
|
23.0
|
L
 -5.2%
H
22.8
24.8
|
L
 0.6%
H
20.8
25.3
|
L
 59.3%
H
14.0
25.3
|
L
 96.2%
H
10.8
25.3
|
L
 60.8%
H
10.8
25.3
|
L
 32.6%
H
10.8
39.8
|
L
H
7.7
51.0
|
L
H
7.7
51.0
|
MiNK Therapeutics Inc |
|
65.9
|
16.5
|
L
 -1.0%
H
16.4
17.7
|
L
 -21.4%
H
16.0
21.5
|
L
 137.0%
H
6.8
76
|
L
 110.4%
H
6.3
76
|
L
 85.8%
H
0.9
76
|
L
 26.3%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
INmune Bio Inc |
|
73.0
|
2.7
|
L
 -15.2%
H
2.6
3
|
L
 11.7%
H
2.4
3.2
|
L
 -49.7%
H
1.9
3.2
|
L
 -65.9%
H
1.9
11.6
|
L
 -67.9%
H
1.9
11.6
|
L
 -70.1%
H
1.9
14.7
|
L
 -76.7%
H
1.9
30.4
|
L
H
1.9
30.4
|
IO Biotech Inc |
|
139.7
|
2.1
|
L
 -3.2%
H
2.1
2.4
|
L
 8.7%
H
1.9
2.5
|
L
 47.2%
H
1.3
2.5
|
L
 125.5%
H
0.9
2.5
|
L
 60.6%
H
0.7
2.5
|
L
 -45.2%
H
0.7
4.7
|
L
H
0.7
17.9
|
L
H
0.7
17.9
|
Iovance Biotherapeutics Inc |
|
891.6
|
2.7
|
L
 -8.6%
H
2.6
3.0
|
L
 -14.7%
H
2.6
4.3
|
L
 58.0%
H
1.7
4.3
|
L
 -25%
H
1.6
4.3
|
L
 -70.5%
H
1.6
12.5
|
L
 -77.1%
H
1.6
18.3
|
L
 -90.7%
H
1.6
54.2
|
L
 -68.3%
H
1.6
54.2
|
Century Therapeutics Inc |
|
49.1
|
0.6
|
L
 -1.7%
H
0.6
0.6
|
L
 -1.7%
H
0.6
0.7
|
L
 9.6%
H
0.5
0.7
|
L
 14%
H
0.5
0.7
|
L
 -74.9%
H
0.3
2.3
|
L
 -94.6%
H
0.3
14
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
Disc Medicine Inc |
|
2,055.5
|
59.4
|
L
 -0.8%
H
59.1
61.6
|
L
 -2.3%
H
58.6
61.7
|
L
 8.9%
H
51.0
62
|
L
 25.9%
H
40.4
62
|
L
 35.4%
H
30.8
68.7
|
L
 287.9%
H
11.8
77.6
|
L
H
11.6
190.9
|
L
H
11.6
190.9
|
ITeos Therapeutics Inc |
|
447.0
|
10.1
|
L
 0.1%
H
10.1
10.2
|
L
H
10.1
10.2
|
L
 1.7%
H
9.9
10.5
|
L
 47.7%
H
6.2
11.4
|
L
 -41.6%
H
4.8
18.1
|
L
 -58.6%
H
4.8
27.5
|
L
 -46.1%
H
4.8
52.4
|
L
H
4.8
52.4
|
Invivyd Inc |
|
90.0
|
0.8
|
L
 -7.4%
H
0.8
0.8
|
L
 -1.3%
H
0.8
0.9
|
L
 2.7%
H
0.7
0.9
|
L
 17.2%
H
0.5
1.1
|
L
 -38.5%
H
0.4
2.7
|
L
 -78.7%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
Immunocore Holdings plc - ADR |
|
1,682.8
|
33.5
|
L
 -1.2%
H
33.0
34.6
|
L
 -9.8%
H
33.0
37.6
|
L
 7.7%
H
30.8
37.6
|
L
 9.9%
H
27.4
39.3
|
L
 -15.7%
H
23.2
40.5
|
L
 -27.4%
H
23.2
77.0
|
L
H
18.4
77.0
|
L
H
18.4
77.0
|
Immutep Limited - ADR |
|
257.6
|
1.8
|
L
 0.6%
H
1.8
1.8
|
L
 4.1%
H
1.7
1.8
|
L
 7.9%
H
1.6
1.8
|
L
 2.3%
H
1.5
2.7
|
L
 -18.4%
H
1.3
2.7
|
L
 -21.7%
H
1.3
3.9
|
L
 27.3%
H
1.2
8.0
|
L
 -58.2%
H
0.5
8.0
|
Inventiva - ADR |
|
447.8
|
3.2
|
L
 2.2%
H
2.9
3.4
|
L
 -2.4%
H
2.9
3.6
|
L
 5.6%
H
2.9
3.7
|
L
 -14.4%
H
2.9
3.9
|
L
 45.7%
H
1.5
4.1
|
L
 -32.9%
H
1.5
11.8
|
L
 -70.0%
H
1.5
19.1
|
L
H
1.5
19.1
|
Janux Therapeutics Inc |
|
1,433.8
|
24.2
|
L
 0.3%
H
23.9
25.1
|
L
 -8.2%
H
23.9
27.3
|
L
 4.7%
H
22.7
28.4
|
L
 -25.6%
H
22.5
34.0
|
L
 -41.9%
H
22.5
71.7
|
L
 95.1%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
Jasper Therapeutics Inc |
|
44.5
|
3.0
|
L
 0.3%
H
2.9
3.1
|
L
 -6.0%
H
2.9
3.3
|
L
 -46.1%
H
2.3
7.2
|
L
 -42.5%
H
2.3
7.2
|
L
 -85.4%
H
2.3
26.1
|
L
 56.6%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
Kamada Ltd |
|
432.4
|
7.5
|
L
 0.1%
H
7.5
7.7
|
L
 -1.6%
H
7.5
7.9
|
L
 -2.5%
H
7.4
8.1
|
L
 13.9%
H
6.4
8.2
|
L
 28.1%
H
5.1
9.2
|
L
 46.6%
H
3.7
9.2
|
L
 -11.5%
H
3.7
13.3
|
L
 94.8%
H
3.1
13.3
|
Kodiak Sciences Inc |
|
385.2
|
7.3
|
L
 -6.4%
H
7.2
8.3
|
L
 30.8%
H
5.6
9
|
L
 97.3%
H
3.6
9
|
L
 75.5%
H
2.8
9
|
L
 143.3%
H
1.9
11.6
|
L
 -26.6%
H
1.4
12.8
|
L
 -84.2%
H
1.4
171.2
|
L
H
1.4
171.2
|
Krystal Biotech Inc |
|
4,427.9
|
153.2
|
L
 0.8%
H
151.9
156.2
|
L
 0.9%
H
147.4
156.2
|
L
 10.3%
H
135.9
156.2
|
L
 -10.2%
H
122.8
172.5
|
L
 -25.3%
H
122.8
212.1
|
L
 111.1%
H
61.1
219.3
|
L
 270.3%
H
38.9
219.3
|
L
H
8.0
219.3
|
TuHURA Biosciences Inc. |
|
120.1
|
2.6
|
L
 -3.7%
H
2.5
2.8
|
L
 -5.8%
H
2.5
3.0
|
L
 16.2%
H
2.2
3.0
|
L
 -34.2%
H
2.1
4.2
|
L
 -68.0%
H
0.2
8.6
|
L
 -99.2%
H
0.2
700
|
L
 -99.9%
H
0.2
5862.5
|
L
 -100.0%
H
0.2
190225
|
Kura Oncology Inc |
|
545.4
|
6.3
|
L
 -1.1%
H
6.2
6.6
|
L
 -5.6%
H
6.2
6.7
|
L
 11.1%
H
5.6
6.7
|
L
 -3.4%
H
5.5
7.2
|
L
 -69.8%
H
5.4
21.6
|
L
 -58.9%
H
5.4
24.2
|
L
 -61.3%
H
5.4
43
|
L
H
2.5
43
|
Kymera Therapeutics Inc |
|
3,091.8
|
44.1
|
L
 0.9%
H
43.9
44.9
|
L
 -3.7%
H
43.2
46.9
|
L
 -0.1%
H
42.9
47.3
|
L
 30.8%
H
28.1
50.3
|
L
 1.0%
H
19.4
53.3
|
L
 100.0%
H
9.6
53.3
|
L
H
9.6
91.9
|
L
H
9.6
91.9
|
Kezar Life Sciences Inc |
|
31.3
|
4.3
|
L
 -0.9%
H
4.3
4.4
|
L
 -3.6%
H
4.2
4.6
|
L
 -3.4%
H
4.1
4.8
|
L
 -2.3%
H
3.8
5
|
L
 -36.9%
H
0.7
9.2
|
L
 -95.6%
H
0.7
108.1
|
L
 -90.2%
H
0.7
185.5
|
L
H
0.7
363.3
|
Longeveron Inc - Ordinary ... |
|
23.7
|
1.6
|
L
 1.3%
H
1.5
1.6
|
L
 -5.4%
H
1.5
1.8
|
L
 19.7%
H
1.3
1.8
|
L
 -1.3%
H
1.1
1.8
|
L
 -54.5%
H
1.1
3.4
|
L
 -97.5%
H
0.8
70.5
|
L
H
0.8
450
|
L
H
0.8
450
|
Lixte Biotechnology Holdin... |
|
11.3
|
3.7
|
L
 -2.6%
H
3.6
3.9
|
L
 -12.2%
H
3.6
4.5
|
L
 418.1%
H
0.7
4.5
|
L
 189.2%
H
0.6
4.5
|
L
 70.3%
H
0.6
4.5
|
L
 -50.4%
H
0.6
27
|
L
 -94.7%
H
0.6
78.6
|
L
 -68.9%
H
0.6
110.4
|
Leap Therapeutics Inc |
|
13.3
|
0.3
|
L
 -3.0%
H
0.3
0.4
|
L
 -8.6%
H
0.3
0.4
|
L
 23.1%
H
0.3
0.4
|
L
 -18.0%
H
0.3
0.5
|
L
 -85.1%
H
0.2
4.8
|
L
 -96.9%
H
0.2
18.6
|
L
 -98.5%
H
0.2
41.7
|
L
H
0.2
102.5
|
Larimar Therapeutics Inc |
|
228.6
|
3.6
|
L
 1.1%
H
3.3
3.9
|
L
 5.6%
H
3.3
4.0
|
L
 17.8%
H
2.8
4.0
|
L
 49.4%
H
1.7
4.0
|
L
 -60.2%
H
1.6
9.5
|
L
 99.4%
H
1.5
13.7
|
L
 -69.6%
H
1.5
25.9
|
L
 -99.2%
H
1.5
575.8
|
LAVA Therapeutics NV |
|
37.4
|
1.4
|
L
 -3.4%
H
1.4
1.7
|
L
 -1.4%
H
1.3
1.7
|
L
 8.4%
H
1.3
1.7
|
L
 12.7%
H
1.2
1.7
|
L
 -29.4%
H
0.9
2.2
|
L
 -45.4%
H
0.9
7.4
|
L
H
0.9
17.2
|
L
H
0.9
17.2
|
Lyell Immunopharma Inc |
|
231.2
|
12.4
|
L
 -3.3%
H
12.2
13.1
|
L
 21.0%
H
10.0
14.2
|
L
 39.2%
H
8.6
14.2
|
L
 44.0%
H
7.7
14.2
|
L
 -60.1%
H
7.7
34.4
|
L
 -88.8%
H
7.7
174.8
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
Microbot Medical Inc |
|
103.6
|
2.6
|
L
 -3.4%
H
2.6
2.7
|
L
 2.4%
H
2.5
3.2
|
L
 3.6%
H
2.4
3.2
|
L
 -1.2%
H
2.3
3.2
|
L
 149.0%
H
0.8
3.4
|
L
 -48.2%
H
0.8
6.1
|
L
 -61.1%
H
0.8
12.2
|
L
 -99.6%
H
0.8
1020.6
|
Seres Therapeutics Inc |
|
125.7
|
14.4
|
L
 18.5%
H
12.2
14.4
|
L
 16.2%
H
12.2
15.4
|
L
 58.2%
H
9
16.0
|
L
 53.2%
H
6.5
16.0
|
L
 907.0%
H
0.4
16.0
|
L
 250.4%
H
0.4
16.0
|
L
 253.8%
H
0.4
38.5
|
L
 -61.7%
H
0.4
52
|
MeiraGTx Holdings plc |
|
634.1
|
7.9
|
L
 -2.2%
H
7.8
8.3
|
L
 -8.2%
H
7.8
8.7
|
L
 19.4%
H
6.3
9.0
|
L
 14.4%
H
4.6
9.0
|
L
 60.4%
H
3.9
9.0
|
L
 -4.7%
H
3.5
11.6
|
L
 -41.6%
H
3.5
24.9
|
L
H
3.5
30.2
|
Mineralys Therapeutics Inc |
|
944.4
|
14.5
|
L
 4.4%
H
14.0
15.2
|
L
 8.6%
H
13.1
15.2
|
L
 5.7%
H
13.1
15.2
|
L
 4.0%
H
13.0
16.9
|
L
 12.9%
H
8.2
18.4
|
L
H
5.9
22.0
|
L
H
5.9
22.0
|
L
H
5.9
22.0
|
Monopar Therapeutics Inc |
|
260.9
|
42.7
|
L
 -0.9%
H
41.7
44.3
|
L
 -5.7%
H
41.5
47.5
|
L
 27.0%
H
32.7
50.1
|
L
 1.7%
H
28.4
50.1
|
L
 1068.8%
H
1.7
54.1
|
L
 335.3%
H
1.4
54.1
|
L
 13.5%
H
1.4
85.1
|
L
H
1.4
240
|
Marker Therapeutics Inc |
|
15.6
|
1.4
|
L
 -2.1%
H
1.4
1.5
|
L
 -12.7%
H
1.4
1.7
|
L
 -5.5%
H
1.4
4.1
|
L
 12.2%
H
1.1
4.1
|
L
 -73.1%
H
1.0
6.0
|
L
 -56.7%
H
0.7
9.7
|
L
 -93.1%
H
0.7
37.7
|
L
 -97.7%
H
0.7
135.5
|
Moderna |
|
12,433.7
|
32.2
|
L
 -1.6%
H
31.9
33.4
|
L
 -1.8%
H
31.9
35.6
|
L
 18.4%
H
26.8
35.6
|
L
 15.6%
H
23.2
35.6
|
L
 -73.7%
H
23.2
125.7
|
L
 -80.4%
H
23.2
217.3
|
L
 -59.6%
H
23.2
497.5
|
L
H
11.5
497.5
|
Mersana Therapeutics Inc |
|
33.7
|
6.8
|
L
 -2.9%
H
6.6
7.0
|
L
 -25.8%
H
6.6
10.3
|
L
 -7.3%
H
6.6
10.3
|
L
 -26.8%
H
6.6
11.5
|
L
 -86.7%
H
6.5
70.8
|
L
 -94.7%
H
6.5
240.5
|
L
 -98.7%
H
6.5
727.3
|
L
H
6.5
727.3
|
Merus N.V |
|
4,927.4
|
66.2
|
L
 0.4%
H
65.4
67.2
|
L
 4.6%
H
62.8
67.2
|
L
 24.9%
H
51.8
67.2
|
L
 46.9%
H
37.9
67.2
|
L
 19.8%
H
33.2
67.2
|
L
 173.6%
H
12.0
67.2
|
L
 397.1%
H
10.2
67.2
|
L
H
7.3
67.2
|
Maravai LifeSciences Holdi... |
|
347.0
|
2.4
|
L
 -2.8%
H
2.4
2.6
|
L
 -4.7%
H
2.4
2.8
|
L
 -2.4%
H
2.3
2.9
|
L
 16.4%
H
2.0
2.9
|
L
 -73.6%
H
1.7
10.0
|
L
 -90.8%
H
1.7
27.8
|
L
H
1.7
63.6
|
L
H
1.7
63.6
|
MaxCyte Inc |
|
224.3
|
2.1
|
L
 -0.5%
H
2.1
2.2
|
L
 -5.8%
H
2.1
2.4
|
L
 -4.1%
H
2.0
2.4
|
L
 -27.5%
H
2
2.9
|
L
 -54.4%
H
2
5.2
|
L
 -61.3%
H
2
7.5
|
L
 29.4%
H
2
17.4
|
L
H
1.6
17.4
|
Mainz Biomed N.V. |
|
7.0
|
1.8
|
L
 -1.1%
H
1.8
1.9
|
L
 -7.5%
H
1.8
2.3
|
L
 33.3%
H
1.3
2.3
|
L
 -48.3%
H
1.3
3.9
|
L
 -86.9%
H
1.3
19
|
L
 -99.5%
H
1.3
446.8
|
L
H
1.3
1200
|
L
H
1.3
1200
|
Mesoblast Ltd - ADR |
|
1,997.2
|
15.6
|
L
 -2.1%
H
15.4
16
|
L
 3.5%
H
15.4
17.6
|
L
 43.0%
H
10.3
17.6
|
L
 31.1%
H
9.9
17.6
|
L
 129.9%
H
5.8
22
|
L
 367.4%
H
1.0
22
|
L
 17.5%
H
1.0
22
|
L
 9.1%
H
1.0
22
|
Molecular Partners AG - ADR |
|
140.1
|
3.8
|
L
 -3.8%
H
3.6
3.8
|
L
 1.9%
H
3.6
4
|
L
 1.1%
H
3.5
4
|
L
 0.8%
H
3.5
4.3
|
L
 -43.5%
H
3.4
12.2
|
L
 -38.6%
H
3.3
12.7
|
L
 -77.8%
H
3.3
32.0
|
L
 -89.3%
H
3.3
38.8
|
Mereo Biopharma Group Plc ... |
|
276.7
|
1.7
|
L
 1.8%
H
1.7
1.8
|
L
 -1.1%
H
1.7
1.9
|
L
 -34.6%
H
1.6
3.1
|
L
 -31.0%
H
1.6
3.1
|
L
 -58.0%
H
1.6
5.0
|
L
 43.8%
H
0.5
5.0
|
L
 -37.6%
H
0.3
5.0
|
L
H
0.3
8.5
|
Nautilus Biotechnology Inc |
|
95.9
|
0.8
|
L
 1.3%
H
0.7
0.8
|
L
 2.7%
H
0.7
0.8
|
L
 10.1%
H
0.7
0.9
|
L
 4.1%
H
0.7
1.0
|
L
 -72.3%
H
0.7
3.1
|
L
 -73.9%
H
0.7
4.7
|
L
H
0.7
25.9
|
L
H
0.7
25.9
|
Nkarta Inc |
|
154.7
|
2.2
|
L
 5.8%
H
2.1
2.3
|
L
 4.8%
H
2.1
2.3
|
L
 31.3%
H
1.6
2.3
|
L
 11.8%
H
1.6
2.3
|
L
 -67.4%
H
1.3
7.0
|
L
 -83.9%
H
1.3
18.5
|
L
 -91.8%
H
1.3
79.2
|
L
H
1.3
79.2
|
Neoleukin Therapeutics Inc |
|
-
|
21.9
|
L
 4.1%
H
21.3
23.8
|
L
 -0.3%
H
20.7
23.9
|
L
 35.3%
H
14.7
23.9
|
L
 21.6%
H
14.7
25.2
|
L
 21.6%
H
14.7
25.2
|
L
 8.3%
H
7.5
25.2
|
L
 -89.1%
H
7.5
359
|
L
 -36.1%
H
7.5
1115
|
9 Meters Biopharma Inc |
|
-
|
6.7
|
L
 -1.2%
H
6.7
6.9
|
L
 -2.6%
H
6.7
7.1
|
L
 1.4%
H
6.6
7.1
|
L
 -5.3%
H
6.3
7.1
|
L
 -5.3%
H
6.3
7.1
|
L
 53.2%
H
0.0
7.1
|
L
 -31.1%
H
0.0
45.2
|
L
H
0.0
1010
|
MetaVia Inc. |
|
11.8
|
0.6
|
L
 -6.3%
H
0.6
0.6
|
L
 -14.3%
H
0.6
0.7
|
L
 -4.8%
H
0.6
0.7
|
L
 -23.1%
H
0.6
0.9
|
L
 -85.8%
H
0.6
4.4
|
L
 -95.3%
H
0.4
63.9
|
L
 -99.7%
H
0.4
228.3
|
L
H
0.4
16192.5
|
Intellia Therapeutics Inc |
|
1,277.2
|
12.3
|
L
 -1.4%
H
12.1
13.1
|
L
 -8.6%
H
12.1
14.6
|
L
 29.0%
H
9.0
14.6
|
L
 50.4%
H
6.8
14.6
|
L
 -54.2%
H
5.9
27.3
|
L
 -81.0%
H
5.9
76.5
|
L
 -32.8%
H
5.9
202.7
|
L
H
5.9
202.7
|
Nuvalent Inc - Ordinary Sh... |
|
5,711.7
|
79.5
|
L
 0.4%
H
78.8
82.1
|
L
 -1.4%
H
76.2
83.5
|
L
 -0.2%
H
76.2
86.8
|
L
 4.8%
H
63.6
86.8
|
L
 0.5%
H
55.5
113.5
|
L
 435.3%
H
14.1
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
Novavax, Inc. |
|
1,109.5
|
6.9
|
L
 -2.3%
H
6.8
7.1
|
L
 -5.1%
H
6.8
8.5
|
L
 7.5%
H
6.2
8.5
|
L
 6.7%
H
5.8
8.8
|
L
 -58.3%
H
5.0
15.2
|
L
 -87.4%
H
3.5
63.2
|
L
 -95.3%
H
3.5
331.7
|
L
 -97.1%
H
3.5
331.7
|
NuCana plc - ADR |
|
19.1
|
0.1
|
L
H
0.0
0.1
|
L
H
0.0
0.1
|
L
 -44.4%
H
0.0
0.1
|
L
 -90.6%
H
0.0
1.3
|
L
 -98.6%
H
0.0
10.8
|
L
 -99.9%
H
0.0
48.8
|
L
 -100.0%
H
0.0
195.8
|
L
H
0.0
800
|
Insight Molecular Diagnost... |
|
77.2
|
2.7
|
L
 -1.1%
H
2.7
2.9
|
L
 -4.9%
H
2.7
3.1
|
L
 -15.6%
H
2.6
3.3
|
L
 -13.5%
H
2.6
4.2
|
L
 -17.4%
H
1.9
4.8
|
L
 -83.9%
H
1.9
22
|
L
 -90.1%
H
1.9
131.4
|
L
H
1.9
204.8
|
OKYO Pharma Limited - Ordi... |
|
94.4
|
2.5
|
L
 -1.2%
H
2.5
2.6
|
L
 -8.7%
H
2.5
2.9
|
L
 2.5%
H
2.4
3.1
|
L
 58.9%
H
1.3
3.1
|
L
 100.8%
H
0.8
3.1
|
L
 6.8%
H
0.8
7
|
L
H
0.8
7
|
L
H
0.8
7
|
Oncolytics Biotech, Inc. |
|
100.5
|
1.0
|
L
 2.0%
H
1
1.1
|
L
 -16.1%
H
1
1.2
|
L
 38.7%
H
0.7
1.4
|
L
 76.3%
H
0.3
1.4
|
L
 -1.0%
H
0.3
1.5
|
L
 -9.6%
H
0.3
3.4
|
L
 -48.8%
H
0.3
4.8
|
L
 -82.1%
H
0.3
8.5
|
Traws Pharma Inc. |
|
8.3
|
1.5
|
L
 -3.9%
H
1.5
1.6
|
L
 -7.4%
H
1.5
1.7
|
L
 4.9%
H
1.4
1.7
|
L
 4.9%
H
1.0
2.6
|
L
 -86.1%
H
1.0
19.4
|
L
 -95.0%
H
1.0
38
|
L
 -99.7%
H
1.0
723.8
|
L
 -100.0%
H
1.0
225000
|
VivoSim Labs Inc. |
|
5.2
|
2.0
|
L
 1.0%
H
2.0
2.2
|
L
 1.0%
H
2.0
2.4
|
L
 36.7%
H
1.4
2.4
|
L
 17.5%
H
1.4
2.4
|
L
 -70.5%
H
0.3
22.0
|
L
 -94.3%
H
0.3
44.6
|
L
 -98.8%
H
0.3
287.0
|
L
 -99.8%
H
0.3
1197.6
|
Passage Bio Inc |
|
19.2
|
6.2
|
L
 -3%
H
6.0
6.6
|
L
 8.5%
H
5.4
7.7
|
L
 -7.1%
H
5.1
9.8
|
L
 -1.4%
H
5.1
10.4
|
L
 -67.3%
H
5.1
26.6
|
L
 -83.6%
H
5.1
45.8
|
L
 -98.3%
H
5.1
617.4
|
L
H
5.1
764.6
|
Vaxcyte Inc |
|
4,491.9
|
34.8
|
L
 0.4%
H
34.5
36.5
|
L
 -2.5%
H
34.5
37
|
L
 6.9%
H
31.8
38.0
|
L
 0.1%
H
28.1
38.4
|
L
 -58.0%
H
27.7
121.1
|
L
 50.9%
H
20.5
121.1
|
L
 13.5%
H
15.5
121.1
|
L
H
15.5
121.1
|
PepGen Inc |
|
45.2
|
1.4
|
L
H
1.3
1.4
|
L
 -1.4%
H
1.3
1.5
|
L
 20%
H
1.1
1.5
|
L
 -9.8%
H
1.1
1.7
|
L
 -92.1%
H
0.9
17.8
|
L
 -87.7%
H
0.9
20
|
L
H
0.9
20
|
L
H
0.9
20
|
Precigen Inc |
|
510.7
|
1.7
|
L
 10.2%
H
1.6
1.9
|
L
 13.8%
H
1.5
1.9
|
L
 21.8%
H
1.4
2.0
|
L
 12.3%
H
1.2
2.0
|
L
 6.8%
H
0.7
2.2
|
L
 10.2%
H
0.7
2.9
|
L
 -60.5%
H
0.7
11.1
|
L
 -97.2%
H
0.7
69.5
|
Phio Pharmaceuticals Corp |
|
11.7
|
2.4
|
L
 -4.3%
H
2.4
2.6
|
L
 -3.6%
H
2.4
3.5
|
L
 12.0%
H
2.2
3.5
|
L
 22.7%
H
1.7
3.5
|
L
 -30.4%
H
1.0
9.8
|
L
 -96.9%
H
0.6
110.4
|
L
 -99.1%
H
0.6
470.9
|
L
 -100.0%
H
0.6
385743.6
|
Pliant Therapeutics Inc |
|
93.3
|
1.5
|
L
 4.1%
H
1.5
1.6
|
L
 -3.2%
H
1.5
1.6
|
L
 21.6%
H
1.1
1.6
|
L
 2.7%
H
1.1
1.7
|
L
 -89.1%
H
1.1
16.1
|
L
 -91.2%
H
1.1
36.6
|
L
 -93.7%
H
1.1
43.9
|
L
H
1.1
43.9
|
Pluri Inc |
|
41.2
|
5.2
|
L
 2.6%
H
5.2
5.2
|
L
 4.2%
H
5.1
5.5
|
L
 2.8%
H
4.6
6.0
|
L
 12.7%
H
3.9
6.1
|
L
 -9.0%
H
3.3
7.1
|
L
 -40.0%
H
0.7
11.6
|
L
 -92.7%
H
0.7
97.2
|
L
 -97.3%
H
0.7
196
|
Prelude Therapeutics Inc |
|
46.3
|
0.8
|
L
 -1.2%
H
0.8
0.9
|
L
 -4.7%
H
0.8
1.0
|
L
 5.1%
H
0.8
1.0
|
L
 -8.9%
H
0.7
1.3
|
L
 -85.0%
H
0.6
6.8
|
L
 -83.6%
H
0.6
8.9
|
L
H
0.6
95.4
|
L
H
0.6
95.4
|
Prime Medicine Inc |
|
527.2
|
3.9
|
L
 2.4%
H
3.8
4.1
|
L
 -13.5%
H
3.7
5.2
|
L
 62.0%
H
2.3
5.2
|
L
 145%
H
1.1
5.2
|
L
 -29.6%
H
1.1
5.9
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
ProKidney Corp - Ordinary ... |
|
358.9
|
2.7
|
L
 -2.9%
H
2.6
2.8
|
L
 -11.8%
H
2.6
3.5
|
L
 301.5%
H
0.5
7.1
|
L
 149.1%
H
0.5
7.1
|
L
 14.5%
H
0.5
7.1
|
L
 -72.7%
H
0.5
14.2
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
Prothena Corporation plc |
|
370.3
|
6.9
|
L
 -0.7%
H
6.7
7.3
|
L
 5.4%
H
6.5
7.3
|
L
 13.2%
H
6.0
7.3
|
L
 -29%
H
4.3
9.6
|
L
 -71.3%
H
4.3
24.2
|
L
 -77.8%
H
4.3
79.7
|
L
 -45.1%
H
4.3
79.8
|
L
 -89.7%
H
4.3
79.8
|
Portage Biotech Inc |
|
-
|
6.2
|
L
 8.8%
H
5.7
6.4
|
L
 6.4%
H
5.6
6.4
|
L
 11.9%
H
5.3
6.4
|
L
 -43.8%
H
5.2
12.2
|
L
 57.4%
H
2.1
23.0
|
L
 -96.9%
H
2.1
210
|
L
 -96.8%
H
2.1
899.5
|
L
 -98.5%
H
0.2
1310
|
Protagonist Therapeutics Inc |
|
3,385.5
|
54.6
|
L
 -0.7%
H
54.1
56.3
|
L
 -0.7%
H
51.6
57.1
|
L
 -1.9%
H
49.4
57.7
|
L
 19.7%
H
41.3
57.7
|
L
 40.7%
H
32.5
60.6
|
L
 448.9%
H
7.2
60.6
|
L
 249.2%
H
6.9
60.6
|
L
H
4.5
60.6
|
PureTech Health Plc - ADR |
|
449.3
|
18.7
|
L
 -2.1%
H
18.2
18.9
|
L
 0.8%
H
18.2
19.6
|
L
 9.0%
H
17.1
19.8
|
L
 6.9%
H
15.9
19.8
|
L
 -20.5%
H
13.3
25
|
L
 -24.1%
H
13.3
38.9
|
L
H
13.3
65.9
|
L
H
13.3
65.9
|
Quince Therapeutics Inc |
|
86.0
|
1.7
|
L
 -1.8%
H
1.6
1.8
|
L
 -6.8%
H
1.6
1.9
|
L
 6.5%
H
1.5
2.1
|
L
 46.0%
H
0.7
2.1
|
L
 123.0%
H
0.5
2.5
|
L
 -15.4%
H
0.5
2.7
|
L
 -96.0%
H
0.5
122.0
|
L
H
0.5
122.0
|
uniQure N.V. |
|
791.7
|
14.5
|
L
 5.7%
H
14.3
16.3
|
L
 1.5%
H
12.3
16.3
|
L
 4.3%
H
12.3
16.3
|
L
 4.3%
H
10.1
17.6
|
L
 85.4%
H
4.5
19
|
L
 -43.0%
H
3.7
28.3
|
L
 -61.7%
H
3.7
52.2
|
L
 -43.9%
H
3.7
82.5
|
Rain Oncology Inc |
|
141.9
|
3.9
|
L
 2.9%
H
3.7
4.0
|
L
 0.3%
H
3.4
4.1
|
L
 17.1%
H
2.9
4.1
|
L
 29.1%
H
2.7
9.2
|
L
 222.3%
H
1.4
9.2
|
L
 -39.3%
H
0.8
14.5
|
L
H
0.8
23.9
|
L
H
0.8
23.9
|
Rani Therapeutics Holdings... |
|
24.0
|
0.6
|
L
 1.9%
H
0.5
0.6
|
L
 25%
H
0.4
0.6
|
L
H
0.4
0.9
|
L
 -50.5%
H
0.4
1.1
|
L
 -81.4%
H
0.4
3.8
|
L
 -95.1%
H
0.4
12.9
|
L
 -99.7%
H
0.4
36.3
|
L
H
0.4
224.5
|
Rocket Pharmaceuticals Inc |
|
338.3
|
3.1
|
L
 4.3%
H
3.1
3.4
|
L
 -6.8%
H
3
3.5
|
L
 24.1%
H
2.4
3.5
|
L
 -56.9%
H
2.2
8.3
|
L
 -87.3%
H
2.2
25.2
|
L
 -78.3%
H
2.2
32.5
|
L
 -86.9%
H
2.2
67.5
|
L
 -95.0%
H
2.2
67.5
|
Replimune Group Inc |
|
587.4
|
7.6
|
L
 101.3%
H
5.7
8.1
|
L
 169.6%
H
2.7
8.1
|
L
 -19.1%
H
2.7
13.2
|
L
 -19.6%
H
2.7
13.2
|
L
 -25.0%
H
2.7
17
|
L
 -60.8%
H
2.7
29.5
|
L
 -62.2%
H
2.7
54.9
|
L
H
2.7
54.9
|
Revelation Biosciences Inc |
|
3.8
|
2.5
|
L
 2.9%
H
2.3
2.9
|
L
 -19.7%
H
2.3
3.2
|
L
 7.5%
H
2.1
3.2
|
L
 -72.5%
H
2.1
10.0
|
L
 -96.6%
H
0.7
168
|
L
 -100.0%
H
0.7
31693.6
|
L
H
0.7
569016
|
L
H
0.7
569016
|
Relay Therapeutics Inc |
|
622.3
|
3.6
|
L
 0.3%
H
3.6
3.8
|
L
 -2.2%
H
3.5
4.0
|
L
 10%
H
3.3
4.0
|
L
 17.1%
H
2.7
4.0
|
L
 -55.8%
H
1.8
10.7
|
L
 -80.9%
H
1.8
33.1
|
L
 -89.4%
H
1.8
64.4
|
L
H
1.8
64.4
|
Avidity Biosciences Inc |
|
4,444.8
|
36.9
|
L
 2.6%
H
36.7
39
|
L
 10.0%
H
32.7
39
|
L
 27.0%
H
27.7
39
|
L
 14.7%
H
25.6
39
|
L
 -20.6%
H
21.5
56
|
L
 126.4%
H
4.8
56
|
L
 34.4%
H
4.8
56
|
L
H
4.8
56
|
TransCode Therapeutics Inc |
|
9.3
|
11.2
|
L
 -5.2%
H
11
11.9
|
L
 18.1%
H
10.3
17.2
|
L
 39.9%
H
7.4
17.2
|
L
 -7.9%
H
6.2
22.0
|
L
 -96.0%
H
6.2
739.2
|
L
 -100.0%
H
6.2
1167936
|
L
H
6.2
5174400
|
L
H
6.2
5174400
|
Recursion Pharmaceuticals ... |
|
2,519.1
|
5.8
|
L
 -2.4%
H
5.7
6.2
|
L
 -11.2%
H
5.7
7.1
|
L
 15.5%
H
4.8
7.2
|
L
 1.6%
H
4.0
7.2
|
L
 -29.1%
H
3.8
12.4
|
L
 -31.3%
H
3.8
16.7
|
L
H
3.8
42.8
|
L
H
3.8
42.8
|
Rhythm Pharmaceuticals Inc. |
|
5,586.6
|
84.7
|
L
 -1.1%
H
84.1
87.1
|
L
 -3.6%
H
84.1
89.3
|
L
 35.0%
H
62.3
94.8
|
L
 29.8%
H
55.3
94.8
|
L
 73.7%
H
40.6
94.8
|
L
 571.9%
H
12.2
94.8
|
L
 310.2%
H
3.0
94.8
|
L
H
3.0
94.8
|
SAB Biotherapeutics Inc |
|
21.0
|
2.3
|
L
H
2.2
2.4
|
L
 -13.4%
H
2.2
2.9
|
L
 33.7%
H
1.7
6.6
|
L
 36.1%
H
1.5
6.6
|
L
 -18.4%
H
1
6.6
|
L
 109.3%
H
0.4
6.6
|
L
H
0.4
12.9
|
L
H
0.4
12.9
|
Sana Biotechnology Inc |
|
983.4
|
4.4
|
L
 -2.0%
H
4.3
4.7
|
L
 -10.5%
H
4.3
5.3
|
L
 55.2%
H
2.6
5.3
|
L
 155.0%
H
1.6
5.3
|
L
 -29.1%
H
1.3
7.3
|
L
 -34.7%
H
1.3
12
|
L
H
1.3
44.6
|
L
H
1.3
44.6
|
Cassava Sciences Inc |
|
104.3
|
2.2
|
L
 -2.3%
H
2.1
2.3
|
L
 -16.3%
H
2.1
2.7
|
L
 23.4%
H
1.8
2.7
|
L
 38.5%
H
1.5
2.7
|
L
 -88.0%
H
1.2
42.2
|
L
 -86.8%
H
1.2
51.6
|
L
 -35.3%
H
1.2
146.2
|
L
 -82.4%
H
0.8
146.2
|
Seer Inc - Ordinary Shares... |
|
127.7
|
2.2
|
L
 -0.5%
H
2.2
2.3
|
L
 0.9%
H
2.1
2.3
|
L
 2.4%
H
2.1
2.3
|
L
 12.4%
H
1.8
2.3
|
L
 9.6%
H
1.6
2.6
|
L
 -75.9%
H
1.5
13.4
|
L
H
1.5
86.6
|
L
H
1.5
86.6
|
Selecta Biosciences Inc |
|
1,989.9
|
12.9
|
L
 -4.1%
H
12.7
14.0
|
L
 5.5%
H
12.1
14.6
|
L
 20.3%
H
10.3
15.6
|
L
 25.2%
H
8.5
15.6
|
L
 25.2%
H
8.5
15.6
|
L
 25.2%
H
8.5
15.6
|
L
 25.2%
H
8.5
15.6
|
L
 25.2%
H
8.5
15.6
|
Sangamo Therapeutics Inc |
|
132.5
|
0.5
|
L
 -5.3%
H
0.5
0.6
|
L
 12.5%
H
0.5
0.7
|
L
H
0.5
0.7
|
L
 -25%
H
0.4
0.8
|
L
 -41.3%
H
0.4
3.2
|
L
 -87.4%
H
0.3
6.4
|
L
 -94.5%
H
0.3
19.4
|
L
 -93.9%
H
0.3
27.5
|
Solid Biosciences Inc |
|
548.0
|
7.1
|
L
H
6.9
7.4
|
L
 13.5%
H
6.3
7.4
|
L
 49.8%
H
4.5
7.4
|
L
 131.8%
H
2.4
7.4
|
L
 -25.6%
H
2.4
10.4
|
L
 -30.1%
H
1.8
15.1
|
L
 -80.8%
H
1.8
173.7
|
L
H
1.8
822.6
|
Summit Therapeutics Inc |
|
19,799.5
|
26.7
|
L
 -0.3%
H
26.3
27.7
|
L
 0.5%
H
26.3
29.1
|
L
 29.4%
H
20.3
29.1
|
L
 12.9%
H
16.0
30.0
|
L
 147.3%
H
8.9
36.9
|
L
 2539.6%
H
0.7
36.9
|
L
 646.8%
H
0.7
36.9
|
L
 107.5%
H
0.7
36.9
|
Syndax Pharmaceuticals Inc |
|
859.6
|
10.0
|
L
 -3.5%
H
9.9
10.8
|
L
 -3.1%
H
9.4
10.8
|
L
 10.5%
H
8.6
10.8
|
L
 -27.1%
H
8.6
14.2
|
L
 -54.6%
H
8.6
23.4
|
L
 -51.0%
H
8.6
29.9
|
L
 -27.5%
H
8.6
29.9
|
L
H
3.4
29.9
|
Sensei Biotherapeutics Inc |
|
9.2
|
7.3
|
L
 7.5%
H
6.9
7.3
|
L
 1.4%
H
6.3
7.9
|
L
 -15.8%
H
6.3
9.3
|
L
 -3.8%
H
5.3
9.3
|
L
 -46.6%
H
5
17.4
|
L
 -80.9%
H
5
45.6
|
L
H
5
530
|
L
H
5
530
|
Senti Biosciences Inc. |
|
46.9
|
1.8
|
L
H
1.8
1.9
|
L
 -9.6%
H
1.8
2.1
|
L
 -16.7%
H
1.8
2.4
|
L
 -43.2%
H
1.8
3.9
|
L
 -24.7%
H
1.5
16.9
|
L
 -94.2%
H
1.5
87.7
|
L
H
0.7
87.7
|
L
H
0.7
87.7
|
Sonnet BioTherapeutics Hol... |
|
20.2
|
3.2
|
L
 -1.2%
H
3.2
3.7
|
L
 -37.5%
H
3.1
5.1
|
L
 187.5%
H
1.1
19.3
|
L
 130%
H
1.1
19.3
|
L
 -53.0%
H
0.7
19.3
|
L
 -99.5%
H
0.7
763.8
|
L
 -100.0%
H
0.7
19441.0
|
L
 -100.0%
H
0.7
1723321.6
|
Spero Therapeutics Inc |
|
121.9
|
2.2
|
L
 -0.9%
H
2.2
2.3
|
L
 -9.5%
H
2.2
2.5
|
L
 -25.9%
H
2.2
3.2
|
L
 225.4%
H
0.6
3.2
|
L
 51.4%
H
0.5
3.2
|
L
 198.6%
H
0.5
3.2
|
L
 -81.9%
H
0.5
23.6
|
L
H
0.5
23.6
|
Scholar Rock Holding Corp |
|
3,591.8
|
37.8
|
L
 1.5%
H
37.1
39.1
|
L
 -5.4%
H
37.0
41.3
|
L
 5.6%
H
33.5
44.0
|
L
 15.4%
H
28.3
44.0
|
L
 313.4%
H
6.8
47.0
|
L
 451.5%
H
5.6
47.0
|
L
 258.9%
H
4.3
70
|
L
H
4.3
70
|
Surrozen Inc |
|
80.4
|
9.4
|
L
 1.5%
H
8.7
9.5
|
L
 8.6%
H
8.2
9.5
|
L
 4.1%
H
8
9.5
|
L
 -10.1%
H
5.9
11.6
|
L
 8.2%
H
5.9
18.2
|
L
 268.2%
H
0.3
18.2
|
L
H
0.3
18.2
|
L
H
0.3
18.2
|
Stoke Therapeutics Inc |
|
702.7
|
12.9
|
L
 3.0%
H
12.6
13.1
|
L
 -5.2%
H
12.3
15.0
|
L
 10.7%
H
11.2
15.0
|
L
 35.3%
H
8.3
15.0
|
L
 -13.0%
H
5.4
16.2
|
L
 -13.0%
H
3.4
22.9
|
L
 -51.2%
H
3.4
71.6
|
L
H
3.4
71.6
|
Shattuck Labs Inc |
|
36.9
|
0.8
|
L
 -8.3%
H
0.8
0.8
|
L
 -3.8%
H
0.8
0.9
|
L
 -9.4%
H
0.7
0.9
|
L
 -7.2%
H
0.7
1.2
|
L
 -81.9%
H
0.7
4.3
|
L
 -79.8%
H
0.7
11.8
|
L
H
0.7
60.5
|
L
H
0.7
60.5
|
60 Degrees Pharmaceuticals... |
|
4.5
|
1.4
|
L
 3.8%
H
1.3
1.4
|
L
 3.8%
H
1.3
1.4
|
L
 -40%
H
1.3
2.7
|
L
 -45.9%
H
1.3
3.7
|
L
 -87.4%
H
1.3
12.7
|
L
H
1.3
519
|
L
H
1.3
519
|
L
H
1.3
519
|
Synlogic Inc |
|
17.8
|
1.5
|
L
 -1.3%
H
1.5
1.6
|
L
 -5%
H
1.5
1.7
|
L
 22.6%
H
1.2
2.0
|
L
 32.2%
H
1
2.0
|
L
 -10.1%
H
0.9
2.0
|
L
 -89.6%
H
0.9
20.3
|
L
 -95.5%
H
0.9
76.7
|
L
H
0.9
1156.1
|
Alaunos Therapeutics Inc |
|
4.7
|
2.9
|
L
 3.6%
H
2.7
3.1
|
L
 -4.0%
H
2.5
3.2
|
L
 -44.1%
H
2.5
6.2
|
L
 20.6%
H
2.0
6.2
|
L
 -24.5%
H
1.3
6.2
|
L
 145.3%
H
0.0
6.2
|
L
 -2.4%
H
0.0
6.2
|
L
 -77.8%
H
0.0
14.9
|
Tscan Therapeutics Inc |
|
102.4
|
1.8
|
L
 0.6%
H
1.8
1.9
|
L
 -2.2%
H
1.8
2.0
|
L
 29.3%
H
1.4
2.0
|
L
 13.8%
H
1.2
2.0
|
L
 -74.4%
H
1.0
7.3
|
L
 -58.8%
H
1.0
9.7
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
Bio-Techne |
|
9,047.0
|
57.7
|
L
 -0.3%
H
57.1
58.5
|
L
 8.6%
H
54.1
60.1
|
L
 11.3%
H
49.7
60.1
|
L
 14.3%
H
46.1
60.1
|
L
 -27.6%
H
46.0
83.6
|
L
 -40.1%
H
46.0
99.3
|
L
 -15.9%
H
46.0
136.0
|
L
 110.5%
H
20.0
136.0
|
Terns Pharmaceuticals Inc |
|
516.2
|
5.9
|
L
 2.8%
H
5.8
6.1
|
L
 -1.5%
H
5.6
6.2
|
L
 54.3%
H
3.7
6.2
|
L
 90.0%
H
2.7
6.2
|
L
 -29.1%
H
1.9
11.4
|
L
 177.5%
H
1.8
14.0
|
L
H
1.5
28.4
|
L
H
1.5
28.4
|
Instil Bio Inc |
|
177.2
|
27.0
|
L
 -4.5%
H
26.7
29.4
|
L
 -5.0%
H
26.7
32.8
|
L
 17.6%
H
20.6
32.8
|
L
 130.5%
H
10.8
42.8
|
L
 121.9%
H
9.9
92
|
L
 378.9%
H
0.3
92
|
L
H
0.3
92
|
L
H
0.3
92
|
Tango Therapeutics Inc |
|
682.9
|
6.3
|
L
 -2.5%
H
6.1
6.7
|
L
 -5.7%
H
6.1
7.2
|
L
 25.8%
H
4.8
7.2
|
L
 363.2%
H
1.0
7.2
|
L
 -35.5%
H
1.0
12.0
|
L
 54.0%
H
1.0
13.0
|
L
H
1.0
18.8
|
L
H
1.0
18.8
|
Entrada Therapeutics Inc |
|
252.0
|
6.6
|
L
 5.6%
H
6.4
6.8
|
L
 4.1%
H
6.2
6.8
|
L
 -3.9%
H
6.1
7.6
|
L
 -25.7%
H
6.1
9.5
|
L
 -60.2%
H
6.1
21.8
|
L
 -48.1%
H
6.1
24.4
|
L
H
5.1
36.9
|
L
H
5.1
36.9
|
Trevi Therapeutics Inc |
|
903.4
|
7.4
|
L
 -1.7%
H
7.3
7.7
|
L
 6%
H
7
8.1
|
L
 32.0%
H
5.4
8.1
|
L
 17.6%
H
5.4
8.1
|
L
 135.6%
H
2.4
8.1
|
L
 142.5%
H
1.0
8.1
|
L
 46.9%
H
0.5
8.5
|
L
H
0.5
10.6
|
Taysha Gene Therapies Inc |
|
716.6
|
2.7
|
L
 4.6%
H
2.7
2.9
|
L
 4.2%
H
2.5
2.9
|
L
 15.1%
H
2.3
2.9
|
L
 50.6%
H
1.8
3.2
|
L
 19.7%
H
1.1
3.3
|
L
 -32.7%
H
0.5
5.1
|
L
H
0.5
33.4
|
L
H
0.5
33.4
|
Twist Bioscience Corp |
|
2,080.9
|
34.7
|
L
 0.1%
H
34.5
35.9
|
L
 -3.1%
H
34.3
37.1
|
L
 -3.3%
H
34.2
39.4
|
L
 -12.5%
H
27.1
42.1
|
L
 -39.5%
H
27.1
58.2
|
L
 -20.6%
H
11.5
60.9
|
L
 -39.7%
H
11.5
214.1
|
L
H
11.5
214.1
|
10x Genomics Inc - Ordinar... |
|
1,712.8
|
13.9
|
L
 -0.6%
H
13.6
14.3
|
L
 7.1%
H
13.0
14.9
|
L
 18.6%
H
11.3
14.9
|
L
 66.0%
H
7.7
14.9
|
L
 -31.5%
H
6.8
24.8
|
L
 -65.4%
H
6.8
63.6
|
L
 -85.9%
H
6.8
209.0
|
L
H
6.8
209.0
|
UroGen Pharma Ltd |
|
888.0
|
19.2
|
L
 1.7%
H
18.9
19.7
|
L
 13.3%
H
16.9
19.7
|
L
 42.5%
H
12.7
19.7
|
L
 78.6%
H
3.4
19.7
|
L
 19.2%
H
3.4
19.7
|
L
 145.2%
H
3.4
24.1
|
L
 -16.1%
H
3.4
28.2
|
L
H
3.4
69.6
|
Vera Therapeutics Inc - Or... |
|
1,345.0
|
21.1
|
L
 1.8%
H
20.7
21.5
|
L
 -5.4%
H
20.5
23.3
|
L
 -6.9%
H
20.5
24.6
|
L
 -12.1%
H
18.8
33
|
L
 -41.1%
H
18.5
51.6
|
L
 22.3%
H
5.2
51.6
|
L
H
5.2
51.6
|
L
H
5.2
51.6
|
Vigil Neuroscience Inc |
|
375.7
|
8.1
|
L
 -0.1%
H
8.0
8.1
|
L
 -0.1%
H
8.0
8.1
|
L
 1.3%
H
7.9
8.1
|
L
 319.3%
H
1.9
8.1
|
L
 73.1%
H
1.3
8.1
|
L
 21.1%
H
1.3
16.8
|
L
H
1.3
18.3
|
L
H
1.3
18.3
|
Vir Biotechnology Inc |
|
724.4
|
5.2
|
L
 -0.2%
H
5.2
5.5
|
L
 -8.6%
H
5.2
5.9
|
L
 1.4%
H
4.9
6.2
|
L
 -12.4%
H
4.3
6.3
|
L
 -50.1%
H
4.3
14.5
|
L
 -81.2%
H
4.3
31.6
|
L
 -89.0%
H
4.3
141.0
|
L
H
4.3
141.0
|
Vor Biopharma Inc |
|
276.2
|
2.2
|
L
 -6.0%
H
2.2
2.3
|
L
 7.8%
H
2.0
2.7
|
L
 108.5%
H
1.1
3.3
|
L
 225%
H
0.1
3.3
|
L
 127.8%
H
0.1
3.3
|
L
 -52.1%
H
0.1
7.6
|
L
H
0.1
63.6
|
L
H
0.1
63.6
|
Verastem Inc |
|
342.3
|
6.2
|
L
 -1.0%
H
6.1
6.8
|
L
 18.2%
H
5.2
6.8
|
L
 50.1%
H
4.0
6.8
|
L
 -10.6%
H
4.0
9.1
|
L
 127.4%
H
2.1
9.1
|
L
 -51.5%
H
2.1
17.5
|
L
 -62.0%
H
2.1
59.2
|
L
 -92.8%
H
2.1
124.2
|
VistaGen Therapeutics Inc |
|
86.0
|
3.0
|
L
 -3.6%
H
2.9
3.2
|
L
 16.1%
H
2.5
3.3
|
L
 49.8%
H
2.0
3.3
|
L
 28.8%
H
1.9
3.3
|
L
 -18.3%
H
1.9
3.8
|
L
 -31.2%
H
1.6
24.7
|
L
 -89.3%
H
1.6
106.5
|
L
 -99.1%
H
1.6
421.5
|
Ventyx Biosciences Inc |
|
191.4
|
2.7
|
L
 0.8%
H
2.6
2.8
|
L
 -10.9%
H
2.6
3.3
|
L
 15.0%
H
2.0
3.4
|
L
 110.2%
H
1.1
3.4
|
L
 18.0%
H
0.8
3.4
|
L
 -82.2%
H
0.8
47.3
|
L
H
0.8
47.3
|
L
H
0.8
47.3
|
Voyager Therapeutics Inc |
|
191.5
|
3.5
|
L
 8.1%
H
3.3
3.8
|
L
 9.5%
H
3.2
3.8
|
L
 16.9%
H
2.9
3.8
|
L
 -3.4%
H
2.6
3.8
|
L
 -62.1%
H
2.6
9.6
|
L
 -48.4%
H
2.6
14.3
|
L
 -69.5%
H
2.5
14.3
|
L
H
2.5
31.9
|
Valneva SE - ADR |
|
650.5
|
7.7
|
L
 -1.4%
H
7.4
7.8
|
L
 22.8%
H
6.4
8.5
|
L
 31.9%
H
5.6
8.5
|
L
 18.6%
H
5.4
8.5
|
L
 7.8%
H
3.6
8.7
|
L
 -62.2%
H
3.6
23.1
|
L
H
3.6
67.8
|
L
H
3.6
67.8
|
Wave Life Sciences Ltd. |
|
1,269.4
|
8.2
|
L
 -1.9%
H
7.8
8.6
|
L
 2.9%
H
7.8
8.9
|
L
 22.3%
H
6.3
8.9
|
L
 11.2%
H
5.6
8.9
|
L
 25.4%
H
5.0
16.7
|
L
 221.3%
H
2.3
16.7
|
L
 -8.0%
H
1.2
20.0
|
L
H
1.2
56
|
XBiotech Inc |
|
88.4
|
2.9
|
L
 1.4%
H
2.8
2.9
|
L
 -5.8%
H
2.8
3.2
|
L
 3.6%
H
2.8
3.3
|
L
 1.1%
H
2.5
3.3
|
L
 -59.9%
H
2.5
8.3
|
L
 -43.9%
H
2.5
10.0
|
L
 -80.4%
H
2.5
21.5
|
L
 -84.8%
H
2.1
26.4
|
Exicure Inc |
|
41.6
|
6.6
|
L
 -0.8%
H
6.5
7.0
|
L
 -17.2%
H
6.5
8.4
|
L
 11.7%
H
5.0
9.5
|
L
 -39.7%
H
5.0
11.9
|
L
 200.5%
H
0.3
36
|
L
 -18.8%
H
0.3
36
|
L
 -98.1%
H
0.3
424.5
|
L
H
0.3
975
|
Xeris Biopharma Holdings Inc |
|
821.6
|
5.1
|
L
 2.6%
H
5.0
5.3
|
L
 0.2%
H
4.9
5.3
|
L
 9.2%
H
4.5
5.5
|
L
 16.3%
H
4.3
5.5
|
L
 103.6%
H
2.1
6.1
|
L
 261.3%
H
1.0
6.1
|
L
 90%
H
1.0
7.9
|
L
H
1.0
28.0
|
X4 Pharmaceuticals Inc |
|
12.7
|
1.8
|
L
 -7.8%
H
1.8
2.0
|
L
 18.8%
H
1.5
2.3
|
L
 -3.3%
H
1.4
2.3
|
L
 -59.3%
H
1.4
4.8
|
L
 105.8%
H
0.2
6.6
|
L
 38.3%
H
0.2
6.6
|
L
 -77.9%
H
0.2
10.7
|
L
H
0.2
172.2
|
Xencor Inc |
|
621.3
|
8.7
|
L
 -1.0%
H
8.6
9.2
|
L
 -5.1%
H
8.6
10.1
|
L
 7.3%
H
7.7
10.1
|
L
 -17.5%
H
7.3
11.7
|
L
 -58.5%
H
7.2
27.2
|
L
 -69.6%
H
7.2
38.2
|
L
 -71.3%
H
7.2
58.3
|
L
 -61.5%
H
7.2
58.3
|
22nd Century Group Inc |
|
1.0
|
2.9
|
L
 -3.6%
H
2.9
3.1
|
L
 -3.3%
H
2.9
3.9
|
L
 -63.8%
H
2.9
9.5
|
L
 -84.2%
H
2.9
32.7
|
L
 -99.9%
H
2.9
2392.2
|
L
 -100.0%
H
2.9
1568646
|
L
 -100.0%
H
2.9
4523364
|
L
 -100.0%
H
2.9
4523364
|
YS Biopharma Co Ltd |
|
31.3
|
0.8
|
L
 -15.6%
H
0.7
1
|
L
 -35.6%
H
0.7
1.4
|
L
 -17.4%
H
0.7
1.5
|
L
 -36.7%
H
0.7
1.5
|
L
 -81.5%
H
0.6
8.5
|
L
 -99.2%
H
0.6
184.4
|
L
H
0.6
184.4
|
L
H
0.6
184.4
|
Zentalis Pharmaceuticals Inc |
|
99.3
|
1.4
|
L
 2.2%
H
1.4
1.5
|
L
 -3.5%
H
1.3
1.5
|
L
 17.0%
H
1.1
1.5
|
L
 0.7%
H
1.1
1.7
|
L
 -66.9%
H
1.0
5.4
|
L
 -95.3%
H
1.0
32.3
|
L
 -96.2%
H
1.0
87.2
|
L
H
1.0
87.2
|
Zura Bio Ltd - Ordinary Sh... |
|
89.1
|
1.4
|
L
 -2.0%
H
1.4
1.5
|
L
 -14.3%
H
1.4
1.8
|
L
 37.1%
H
1
2.2
|
L
 3.6%
H
1.0
2.2
|
L
 -64.2%
H
1.0
5.1
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
Zai Lab Limited - ADR |
|
4,257.6
|
38.6
|
L
 -4.8%
H
37.2
38.9
|
L
 4.2%
H
36.5
41.2
|
L
 11.0%
H
32.3
41.2
|
L
 21.1%
H
27.6
44.3
|
L
 105.3%
H
16.0
44.3
|
L
 -4.8%
H
13.5
54.0
|
L
 -48.5%
H
13.5
193.5
|
L
H
13.5
193.5
|
Apogee Therapeutics Inc. |
|
2,193.1
|
37.6
|
L
 -0.8%
H
36.8
38.3
|
L
 -5.0%
H
36.8
42.3
|
L
 -13.3%
H
35.7
47.7
|
L
 -0.5%
H
34.4
47.7
|
L
 -24.1%
H
26.2
63.5
|
L
H
14.2
72.3
|
L
H
14.2
72.3
|
L
H
14.2
72.3
|
Turnstone Biologics Corp |
|
8.1
|
0.4
|
L
 -2.8%
H
0.4
0.4
|
L
 -2.8%
H
0.4
0.4
|
L
H
0.4
0.4
|
L
 2.9%
H
0.3
0.4
|
L
 -85.9%
H
0.3
2.6
|
L
H
0.3
13.2
|
L
H
0.3
13.2
|
L
H
0.3
13.2
|
Intensity Therapeutics Inc |
|
7.8
|
0.3
|
L
 -6.3%
H
0.3
0.3
|
L
 -3.2%
H
0.3
0.4
|
L
 -6.3%
H
0.3
0.4
|
L
 -50%
H
0.3
0.7
|
L
 -93.5%
H
0.3
4.9
|
L
 -92.5%
H
0.3
11.4
|
L
 -92.5%
H
0.3
11.4
|
L
 -92.5%
H
0.3
11.4
|
Renovaro Biosciences Inc |
|
63.2
|
0.3
|
L
 -3.5%
H
0.3
0.3
|
L
 -9.7%
H
0.3
0.4
|
L
 -3.5%
H
0.3
0.4
|
L
 -17.7%
H
0.3
0.6
|
L
 -76.3%
H
0.3
2.1
|
L
H
0.3
5.3
|
L
H
0.3
5.3
|
L
H
0.3
5.3
|
Elutia Inc - Ordinary Shar... |
|
80.6
|
2.0
|
L
 6.5%
H
1.8
2.1
|
L
 -6.7%
H
1.8
2.2
|
L
 -6.7%
H
1.8
2.6
|
L
 -12.5%
H
1.6
2.6
|
L
 -47.2%
H
1.6
5.1
|
L
H
1.1
5.2
|
L
H
1.1
5.2
|
L
H
1.1
5.2
|
Tharimmune Inc |
|
5.6
|
1.3
|
L
 -1.5%
H
1.3
1.3
|
L
 -18.5%
H
1.3
1.7
|
L
 -26.7%
H
1.3
2.0
|
L
 -10.8%
H
1.3
2.0
|
L
 -58.9%
H
1.0
6.4
|
L
 -99.7%
H
0.3
993.8
|
L
H
0.3
1590
|
L
H
0.3
1590
|
Gyre Therapeutics Inc |
|
659.1
|
7.3
|
L
 -0.4%
H
7.1
7.5
|
L
 0.6%
H
7.1
7.9
|
L
 -2.0%
H
7.0
8.2
|
L
 -24.0%
H
7.0
11.8
|
L
 -51.2%
H
6.1
19
|
L
 -3.1%
H
5.6
130.5
|
L
 -3.1%
H
5.6
130.5
|
L
 -3.1%
H
5.6
130.5
|
Lexeo Therapeutics Inc. |
|
251.0
|
4.7
|
L
 13.4%
H
4.4
5.1
|
L
 19.5%
H
3.6
5.1
|
L
 12.9%
H
3.6
5.1
|
L
 30.3%
H
2.4
5.6
|
L
 -62.9%
H
1.5
13.6
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
Korro Bio Inc. |
|
152.7
|
16.3
|
L
 7.3%
H
15.5
16.8
|
L
 14.6%
H
14.2
17.8
|
L
 35.2%
H
11.8
17.8
|
L
 -2.5%
H
10.3
22.2
|
L
 -66.8%
H
10.3
98
|
L
H
10.3
98
|
L
H
10.3
98
|
L
H
10.3
98
|
CARGO Therapeutics Inc |
|
207.9
|
4.5
|
L
 -0.5%
H
4.4
4.5
|
L
 -0.5%
H
4.4
4.6
|
L
 6.7%
H
4.1
4.8
|
L
 -1.5%
H
3.8
4.8
|
L
 -73.7%
H
3
25.2
|
L
H
3
33.9
|
L
H
3
33.9
|
L
H
3
33.9
|
Cartesian Therapeutics Inc |
|
333.5
|
12.9
|
L
 -4.1%
H
12.7
14.0
|
L
 5.5%
H
12.1
14.6
|
L
 20.3%
H
10.3
15.6
|
L
 8.0%
H
8.5
15.6
|
L
 -25.2%
H
8.5
26.5
|
L
 -99.1%
H
8.5
2457
|
L
 -99.4%
H
8.5
5130
|
L
H
8.5
25199.6
|
Elevai Labs Inc. |
|
3.1
|
2.2
|
L
H
2.2
2.3
|
L
 -6.3%
H
2.2
2.4
|
L
 3.7%
H
2.1
2.9
|
L
 -5.1%
H
1.9
3.2
|
L
 -99.7%
H
1.9
654.5
|
L
H
1.9
5941.9
|
L
H
1.9
5941.9
|
L
H
1.9
5941.9
|
Spyre Therapeutics Inc. |
|
1,043.5
|
17.3
|
L
 3.1%
H
16.8
17.7
|
L
 4.9%
H
16.4
18.3
|
L
 13.6%
H
14
18.3
|
L
 15.1%
H
12.3
19.2
|
L
 -42.3%
H
10.9
40.3
|
L
H
8.8
48.0
|
L
H
8.8
48.0
|
L
H
8.8
48.0
|
Neurogene Inc |
|
311.9
|
21.9
|
L
 4.1%
H
21.3
23.8
|
L
 -0.3%
H
20.7
23.9
|
L
 35.3%
H
14.7
23.9
|
L
 67.8%
H
11.8
25.2
|
L
 -47.1%
H
6.9
74.5
|
L
 54.2%
H
6.9
74.5
|
L
 54.2%
H
6.9
74.5
|
L
 54.2%
H
6.9
74.5
|
Cg Oncology Inc. |
|
2,051.2
|
26.9
|
L
 3.3%
H
26.3
28.5
|
L
 3.5%
H
25.1
28.5
|
L
 3.7%
H
24.5
29
|
L
 -0.1%
H
21.0
30.2
|
L
 -14.1%
H
14.8
40.4
|
L
H
14.8
50.2
|
L
H
14.8
50.2
|
L
H
14.8
50.2
|
FibroBiologics Inc |
|
26.5
|
0.6
|
L
 4.9%
H
0.6
0.7
|
L
 -4.5%
H
0.6
0.7
|
L
 3.2%
H
0.6
0.7
|
L
 -38.5%
H
0.6
1.1
|
L
 -87.3%
H
0.6
5.5
|
L
H
0.6
55
|
L
H
0.6
55
|
L
H
0.6
55
|
Kyverna Therapeutics Inc. |
|
162.5
|
3.8
|
L
 -2.3%
H
3.7
4.0
|
L
 -8.3%
H
3.7
4.6
|
L
 14.6%
H
2.5
4.6
|
L
 84.3%
H
1.9
4.6
|
L
 -60.3%
H
1.8
9.7
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
Metagenomi Inc. |
|
84.9
|
2.3
|
L
 -3.4%
H
2.3
2.5
|
L
 -2.6%
H
2.2
2.9
|
L
 55.5%
H
1.5
2.9
|
L
 37.6%
H
1.4
2.9
|
L
 -47.6%
H
1.2
4.9
|
L
H
1.2
15
|
L
H
1.2
15
|
L
H
1.2
15
|
Tevogen Bio Holdings Inc. |
|
197.6
|
1.0
|
L
 -1.9%
H
1
1.1
|
L
 -8.1%
H
1
1.1
|
L
 -17.7%
H
1
1.4
|
L
 1.0%
H
0.9
1.5
|
L
 52.2%
H
0.3
3.1
|
L
H
0.3
21.1
|
L
H
0.3
21.1
|
L
H
0.3
21.1
|
NeOnc Technologies Holding... |
|
94.6
|
5.0
|
L
 -0.4%
H
4
5
|
L
 2.7%
H
4
6.0
|
L
 35.1%
H
3.2
7.7
|
L
H
3.2
8.8
|
L
H
3.2
8.8
|
L
H
3.2
8.8
|
L
H
3.2
8.8
|
L
H
3.2
8.8
|
LENZ Therapeutics Inc. |
|
865.8
|
30.8
|
L
 -2.9%
H
30.7
32.6
|
L
 -6.7%
H
30.7
34.9
|
L
 1.9%
H
28.8
36.0
|
L
 15.5%
H
22.5
36.0
|
L
 27.7%
H
16.5
38.9
|
L
 23.4%
H
14.4
38.9
|
L
 23.4%
H
14.4
38.9
|
L
 23.4%
H
14.4
38.9
|
Boundless Bio Inc. |
|
26.6
|
1.2
|
L
H
1.2
1.2
|
L
H
1.2
1.3
|
L
 17.8%
H
1.0
1.3
|
L
 -25.6%
H
1
1.8
|
L
 -69.2%
H
1
4.7
|
L
H
1
14.7
|
L
H
1
14.7
|
L
H
1
14.7
|
Contineum Therapeutics Inc... |
|
155.5
|
6.0
|
L
 15.6%
H
5.2
6.0
|
L
 16.0%
H
5.1
6.0
|
L
 46.2%
H
3.7
6.0
|
L
 36.3%
H
3.4
6.0
|
L
 -71.6%
H
3.4
21.3
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
Eupraxia Pharmaceuticals Inc |
|
189.6
|
5.3
|
L
 -5.2%
H
5.2
5.6
|
L
 3.1%
H
5.0
5.7
|
L
 -0.2%
H
4.9
6.2
|
L
 34.6%
H
3.7
6.2
|
L
 87.6%
H
2.2
6.2
|
L
H
2.2
6.2
|
L
H
2.2
6.2
|
L
H
2.2
6.2
|
Entero Therapeutics Inc. |
|
2.2
|
0.5
|
L
 -2.1%
H
0.5
0.5
|
L
 -8%
H
0.5
0.5
|
L
 21.1%
H
0.4
0.6
|
L
 31.4%
H
0.3
0.7
|
L
 -32.4%
H
0.2
0.9
|
L
 -83.5%
H
0.2
3.2
|
L
 -83.5%
H
0.2
3.2
|
L
 -83.5%
H
0.2
3.2
|
Artiva Biotherapeutics Inc |
|
72.6
|
3.0
|
L
 2.4%
H
2.9
3.2
|
L
 15.5%
H
2.6
3.7
|
L
 102.7%
H
1.5
3.7
|
L
 21.6%
H
1.5
3.7
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
MBX Biosciences Inc. |
|
517.7
|
15.5
|
L
 3.5%
H
14.6
15.9
|
L
 32.4%
H
11.7
15.9
|
L
 44.1%
H
10.6
15.9
|
L
 56.9%
H
9.4
15.9
|
L
H
4.8
27.5
|
L
H
4.8
27.5
|
L
H
4.8
27.5
|
L
H
4.8
27.5
|
BioAge Labs Inc. |
|
158.5
|
4.4
|
L
 -1.3%
H
4.3
4.6
|
L
 -7.1%
H
4.3
4.9
|
L
 5.2%
H
4.1
4.9
|
L
 2.1%
H
3.7
4.9
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
OnKure Therapeutics Inc. -... |
|
30.8
|
2.3
|
L
 0.9%
H
2.3
2.3
|
L
 1.8%
H
2.3
2.4
|
L
 -5%
H
2.2
2.8
|
L
 -9.9%
H
1.7
3.2
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
CAMP4 Therapeutics Corp. |
|
-
|
1.7
|
L
 -1.2%
H
1.6
1.7
|
L
 -1.2%
H
1.6
2.0
|
L
 8.6%
H
1.3
2.0
|
L
 -28.3%
H
1.3
2.2
|
L
 -28.3%
H
1.3
2.2
|
L
 -28.3%
H
1.3
2.2
|
L
 -28.3%
H
1.3
2.2
|
L
 -28.3%
H
1.3
2.2
|
Upstream Bio Inc. |
|
817.1
|
15.2
|
L
 8.7%
H
14.0
15.5
|
L
 41.3%
H
10.9
15.5
|
L
 39.0%
H
10.5
15.5
|
L
 69.2%
H
7.8
15.5
|
L
H
5.1
29.5
|
L
H
5.1
29.5
|
L
H
5.1
29.5
|
L
H
5.1
29.5
|
Medicus Pharma Ltd |
|
41.1
|
2.5
|
L
 -3.5%
H
2.4
2.7
|
L
 -18.8%
H
2.4
3.1
|
L
 -13.8%
H
2.4
3.7
|
L
 -62.9%
H
2.3
8.9
|
L
 -62.9%
H
2.3
8.9
|
L
 -62.9%
H
2.3
8.9
|
L
 -62.9%
H
2.3
8.9
|
L
 -62.9%
H
2.3
8.9
|
Telix Pharmaceuticals Ltd.... |
|
4,518.8
|
13.5
|
L
 0.1%
H
13.3
13.7
|
L
 -17.1%
H
13.3
14.8
|
L
 -15.6%
H
13.3
17.0
|
L
 -22.2%
H
13.3
19.0
|
L
H
13.3
30.4
|
L
H
13.3
30.4
|
L
H
13.3
30.4
|
L
H
13.3
30.4
|
Palvella Therapeutics Inc. |
|
413.9
|
37.4
|
L
 -3.7%
H
36.8
39.2
|
L
 4%
H
35.7
40.5
|
L
 69.6%
H
21.6
40.5
|
L
 59.7%
H
20.2
40.5
|
L
 175.3%
H
11.2
40.5
|
L
 175.3%
H
11.2
40.5
|
L
 175.3%
H
11.2
40.5
|
L
 175.3%
H
11.2
40.5
|
Sionna Therapeutics Inc. |
|
782.6
|
17.8
|
L
 -3.2%
H
17.7
19.6
|
L
 -6.7%
H
17.2
20.6
|
L
 12.1%
H
15.1
21.9
|
L
 47.4%
H
11.0
21.9
|
L
H
7.3
25.2
|
L
H
7.3
25.2
|
L
H
7.3
25.2
|
L
H
7.3
25.2
|
Zenas Biopharma Inc. |
|
658.9
|
15.8
|
L
 -1.9%
H
15.1
16.7
|
L
 10.1%
H
14.3
16.7
|
L
 64.4%
H
8.9
16.7
|
L
 50.4%
H
8.9
16.7
|
L
 50.4%
H
8.9
16.7
|
L
 50.4%
H
8.9
16.7
|
L
 50.4%
H
8.9
16.7
|
L
 50.4%
H
8.9
16.7
|